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Development of a new medication is not an easy task being not only 
financially costly but also very time consuming without any guarantee of 
success. Information about medications that has been developed and used 
until now is well accumulated due to technological advances, especially IT 
technology. This information has allowed more thorough inspection of safety 
of existing medications. Also, in case of any safety problem, certain 
medication could be withdrawn from the market. A newly magnified side 
effect can give a different perspective so that a change in indication leads to 
the use of new medication. Mechanism of action and target are not clearly 
known for all medications, but research on unknown medications is ongoing 
and those new information are being recorded as big data. In addition, gene 
information of organisms is continuously being added to the data base and 
offered to the public research for the health and prolonged life of humanity. 
Usage of thalidomide had once been stopped due to a risky side effect, 
however, the mechanism of action that caused certain side effect has been 
verified and it is now being used to treat multiple myeloma with a new 
indication. This was possible because there has been sufficient research on 




to examine the effectiveness of pre-existing medications that are used for off-
label indications. Under the current circumstance where reference is rare and 
clinical trials are not possible, this research will study the validity of off-label 
uses of many drugs to determine whether there are any safety issues based on 
the accumulated information. On the other hand, this research will give 
theoretical propriety to well-known off-label uses that pharmaceutical 
companies avoid due to lack of economic profit. Also, this research will 
suggest that the process of finding a new indication of a new substance can be 
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CHAPTER  I.  INTRODUCTION 
 
 
1.1 The Background of Study 
Development of a new medication is not an easy job being not only 
financially costly but also very time consuming without any guarantee for 
clinical effectiveness or safety, if it is ever used. Therefore, recently there has 
been a repositioning of old medication for the new purpose of cure or 
paradoxical treatment, which was originally designed to cure a certain disease 
yet by using the revealed side effects it is now used differently. It has been 
more favorably used than the original treatment purpose. There could be a lot 
of different approaches which make this development possible and the method 
of bio information which uses accumulated information of medications could 
be a more efficient way to reposition existing medications. These studies have 
been done and still are under process in different aspects. The repositioning of 
existing medications can be considered as a stage of developing medication 
processes, and for pharmaceutical companies it is the most important process 
to find the medication which has a high possibility of being used clinically. 
Thalidomide, developed in Europe and once widely used to prevent 
morning sickness for pregnant women, was removed after being confirmed as 
a drug which causes fetus malformation. However, it is now used as an 
essential cure for the complication of Hansen’s disease and Multiple Myeloma, 
though it has limited uses for safety reasons. This medication was launched by 






from the market due to the problem of causing malformation at birth in 1961. 
In 1964, once Thalidomide was proven to be effective on pain relief for 
Hansen’s disease, Celgene got permission for it as a cure of ENL (Erythema 
Nodosum Leprosum), a Hansen’s disease complication, and re-launched it 
after clinical experimentation for anti-inflammation cure. After this, the study 
of mechanism of causing malformation by Thalidomide was conducted a lot. 
As a result, it became known that Thalidomide restrains the formation of the 
new blood vessel in the early stage of pregnancy when baby’s limbs are being 
formed. Based on this, the attempt of study of using Thalidomide as an 
anticancer drug which restrains the new blood vessel for growing cancer cells 
was tried, 2006 Celgene launched it as the cure of Multiple Myeloma (Lee 
Hyun-gyu, 2011). Thalidomide is exclusively permitted as the safe and 
effective alternative medicine only for patients who have Hansen’s disease, 
and no other medications could have effect of remedial value. The conversion 
of Thalidomide as an anti-cancer drug is the result of changing the target 
focused on the side effect, and it became an undependable remedy for non-
curable disease. Propecia was originally developed as a remedy for 
Prostatomegaly under the name of Proscar. However focusing on the fact that 
it boosts hair growth as a side effect, with changing the indication for the use 
of a medication it changes the target of medication and proper dosage and 
then they got the permission to launch becoming really popular. Even now 
there are many medications being used for uses other than the original 
purpose of a medication. The reason is that along the process of the use of the 
original indication for the use of a medication, unintentional clinical results 
were witnessed and the result of different uses other than the original use from 
the permission has accumulated, under the tacit agreement it was to be used as 






uses of these medications for other usages, some of the medications have 
become considered to have got permitted for other uses. However the over-
use of those medications beyond the permission should be go through clinical 
experiments or if that is not possible, at least getting the adequacy of usage is 
the essential process. 
Off-label use of the medications beyond the permission means 
medications are differently used beyond the contents reported to the 
authorities and stated in the permission in the matter of the indication for the 
use of a medicine, dosage, dosing methods and dosing subjects. In the book of 
“The use of medical supplies off-label use and basis-centered decision-
making” (Shin Joo-young et al., 2009), it defines that permitted medical 
supplies are only prescribed and used as it is stated under the permission from 
the authorities in the matter of the indication for the use of a medicine, dosage 
and dosing methods and on the other hand, non-permitted medical supplies 
mean they didn’t get the permission from the authorities and the medications 
were modified and compounded in different forms. Off-label use meant they 
got the permission from the authorities, yet they are used differently from one 
of any of the stated usages in the matter of the indications for the use of a 
medicine, dosage and dosing methods. Let’s take look at the Ministry of Food 
and Drug Safety on terminology. In 2013, the Ministry of Food and Drug 
Safety, Drug Review Management Department, TF team made an initial 
presentation on ‘the legal, practical perspectives of the use of off-label’ at the 
‘Korean Society for Clinical Pharmacology and Therapeutics’ and ‘Korean 
Pharmaceutical Manufactures Medical Society’ spring symposium which is 
held at Seoul University Hospital. It contains the fact that there has been an 
actual request for the granting of usage of medical supplies beyond 






are limited due to the characters of diseases, the narrow indication for the use 
of a medicine and the lack of the number of cases. In 2008, to ensure the 
proper medical treatment when it has the medical base, the Ministry of Health 
made the improved methods of medical supplies permission and usage, and 
then legislated ‘The standard and protocol for the granting of beyond usage of 
permission or reported contents without insurance cover’. In 2010, MFDS 
(Ministry of Food and Drug Safety) made the basis to evaluate the safety and 
effectiveness. However with a lot of practical reasons, the use of off-label has 
not yet been settled, therefore MFDS introduced the protocol for the use of 
off-label use through this presentation. Off-label use is being used by the 
name of ‘Over-used beyond permission Medications’ and it indicates the 
medications are prescribed beyond the granted usages (effect & efficacy, 
usage & dosage) or permitted medications under the pharmaceutical law are 
used differently in medical field. They try to change the term into ‘the off-
label use’. There are two purposes. One is for clinical reasons of researchers 
and the other is for the use differently other than permission. For the clinical 
reasons of the researchers, it gets the permission from the Ministry of Food 
and Drug Safety because it is to make the basis of use of medications beyond 
the permission, while the use is different from that for which permission is 
granted by the Health Insurance Review & Assessment Service based on the 
legislated basis (Medical News, Kim Chang-won, 2013). 
Depending on which organizations use the terms, the terms related to 
off-label use are of mix-used in Korea. Precisely speaking, the use of medical 
supplies, usage, dosing methods and dosing subjects are only permitted as it 
was reported and other than this, everything else becomes off-label use. It is 
the same meaning of the expression of ‘off-label use’ in English spoken 






the old, pregnant women, terminally-ill patients and terminal cancer patients 
who don’t have any other options. Table 1.1 shows the catalog of the off-label 
use medications which requested the permission for the use from the Ministry 
of Food and Drug Safety. Although an anticancer drug is frequently used as an 
off-label medication, it is excluded from this chart because it is regularly 
judged for the effectiveness and the safety not like others due to this disease’s 
critical character. According to the research, 80% of children patients, 50% of 
cancer patients and 81%of AIDS patients are prescribed at least more than one 
off-label use medication. It also says about one-fifth of all the medications are 
used as off-label use, and when it comes to psychiatric medications the use of 
off-label goes up to 31% (Radley et al., 2006). Sorted by diseases, in the use 
of medications for heart related diseases and anti-seizure the off-label use 
medications are more commonly used, yet 73% of use does not have any 
scientific basis or weak basis. In another research, it is said that the 62% of 
pediatric prescription is off-label use (Bazzano et al., 2009). 
There are many cases that are backed up by documents for the 
medications which are frequently used as off-label use medications. However, 
all the documents are the compilation of cases or the reviews of high-profile 
clinical experts’. Very rarely, the result of a large scale clinical experiment 
could be used as a basis, but it is just a temporary status of the off-label use as 
a part of the process of getting permission. To get the permission to launch the 
medications, it has to get through different stages of complicated and strict 
processes and then it can be launched after getting the permission for the 
effects and the side-effects which are proved and stated. However, checking 
the cases of the side-effects through the post marketing surveillance system, it 
can be concluded that the information of effectiveness and safety is limited for 






Marketing Surveillance System (by FDA) becomes an essential request to 
discover the new indications for the use of a medicine and safety issues. 
Another perspective, it is the temporary situation that the use off-label 
medications are clinically used first, and then the authorities which need more 
general and objective proofs ask for improvement and limit the use. 
The reasons for prescribing off-label use medication are that the 
indications for the use of a medicine, usage, dosing methods and dosing 
patients. It is ethically difficult to have clinical experiments with children or 
the old and therefore the clinical experiment of medication on these age 
groups is not required. Those medications which are used in the market can 
result in the over-dose depending on ages because of the lack of the 
information of the child, or the modification of the medication can result in 
the high rate of off-label use for the child. In the case of rare incurable 
diseases, it is difficult for pharmaceutical companies to do clinical 
experiments even though it is possible, it is not profitable for the companies, 
comparing; expenses for the experiments and the permission to market; 
therefore they do not attempt to do it. When there are no alternative 
medications for rare incurable diseases, the authorities of regulation should 
urge the pharmaceutical companies or research institutions to make the basis. 
In this situation, if there is a systematical, more objective, proper and usable 









Table 1.1 Off Label used drug claimed for appropriateness and safety for specific 
diseases in Korea 
generic name indication off-label use 
Naltrexone 
Opioid dependence, alcohol 
dependence 
Internet addiction, Pathological 
Gambling 
Deferiprone 
Iron chelator indicated for 
treatment of transfusional iron 
overload caused by thalassemia 
syndromes  
 Iron overload caused by blood 
transfusion 
Leflunomide 
Rheumatoid Arthritis, .Psoriatic 
arthritis 










nephrotic syndrome in children,  






Rheumatoid Arthritis, Psoriasis 
Chronic non-infectional ocular 
inflammatory disease  
Misoprostol 
NSAID-induced gastric ulcer, 
prophylaxis  




Organ transplant rejection 
prophylaxis  
Lupus  




Central serous chorioretinopathy  
Bortezomib Multiple myeloma  
 Pre medication for transplant to 
sensitized patients, acute rejection 
after renal transplant 
Sirolimus 
Renal transplant rejection, High 
immunologic risk; Prophylaxis  
PTLD(Post-transplant 
lymphoproliferative disorder) of 














Prophylaxis - Percutaneous 
coronary intervention; Adjunct  
1.Cerebrovascular disease, re-
occlusion after brain clots dissolved   
2. Acute cerebrovascular thrombosis 
after nerve intercession operation 
Erythropoietin 
Anemia due to chronic renal 
failure, zidovudine therapy in 
HIV-infected patients, and 
chemotherapy  
Pure red blood cell anemia after 
transplant of homogeneous 
hematopoietic stem cell  
Etanercept 
Rheumatoid arthritis, psoriatic 
arthritis  





symptomatic treatment  
Necrotizing pancreatitis, acute; 
Adjunct, neonate chylothorax, 
Metastatic neuroendocrine tumor  
Imatinib 
Acute lymphoid leukemia, 
Chronic myeloid leukemia, 
Gastrointestinal stromal tumor 
Fibrous-sclerous chronic GVHD  
EGF Diabetic foot ulcers Radiation-induced stomatitis 
Indigocarmin Renal function test  
Diagnosis & management of tubal 
factor infertility  
Quetiapine Schizophrenia, bipolar disorder  delirium  
Clonazepam Seizure, panic disorder  
Parkinsonism, REM sleep disorder, 
tremor  
Tacrolimus 
Severe atopic dermatitis 
(second-line), organ transplant 
rejection; Prophylaxis  
 Vitiligo, Psoriasis, scleroderma, 
facial lupus 
Progesteron 
Abnormal uterine bleeding 
unrelated to menstrual cycle, 
Endometrial hyperplasia; 
Prophylaxis  
Premature birth of newborn, Short 






1.2 The Study of Effectiveness and Safety of the 
Off-Label Use of Medications 
 
Awareness of the effectiveness and safety of off-label use of 
medications was started in 2009 in Korea. It was started in July, 2010. There 
was a questionnaire and request for understanding the current situation of the 
off-label use medication and safety evaluation, MFDS (the Ministry of Food 
and Drug Safety) took over the request document from the Health Insurance 
Review & Assessment Service, and started evaluating the safety and 
effectiveness. Before then under the pharmaceutical law, hospitals or medical 
institutes applied for the approval of use of the medication for the off-label 
use, and then the Health Insurance Review & Assessment Service replied back 
with the possibility of the use. The committee consisted of medical experts, 
who examined the submitted documents along with added research documents, 
and then decided on the adequacy of the off-label use. Based on the result of 
the adequacy of the off-label use, which was decided by each area’s experts’ 
judgment and experience the HIRA (the Health Insurance Review & 
Assessment Service) informed the adequacy of the medication and the 
entitlement of insurance to the medical institutes. This process had more to do 
with the medical insurance policy because its priority focused on the 
discretion of the entitlement of insurance for the medications which were used 
differently as off-label use; in other words, when some of the off-label 
medication was applied; if there was positive effect of treatment and whether 
it would be entitled for medical insurance. 
After the assessment task of the off-label use medications was 






safety become very important sectors. According to the MFDS’s definition1, 
‘off-label use medications’ means due to the disease’s characters which are 
owned by different patients and the limitation of clinical experiments, the 
medications are used in the field based on research and clinical experiences 
beyond the limit of the permission for the medications. The purpose of the 
assessment is to pursue the proficiency of the assessment and management of 
the task by setting the standards - the objective of the assessment, assessment 
standard and the lists of actions for the result - for the safety and the adequacy 
of the medications which are used beyond the limit of the permission. The 
objectives of the assessment: 1) the items are requested to be examined by 
HIRA based on the standard and process of approval for the use of the 
medications beyond the limit of permission or report not covered by insurance, 
2) the items are requested by the Korean Medical Association, the Korean 
Pharmaceutical Association or related organizations concerning the safety and 
the adequacy, 3) the items are considered as items to be assessed concerning 
the safety and the adequacy by the chief of MFDS and the chief of MFDS will 
assess the items first which cause some safety issues related to the 
medications for children or pregnant women. The references for the 
assessment: 1) the references which are submitted by the requester (or the 
organization) related to the safety and adequacy, 2) the references which were 
submitted to MFDS for the application of the permission(report): (these 
include the results of clinical trials which were conducted under the approval 
from MFDS, the results of re-examination for the new medications, the 
references related to the information of the safety and so on), 3) the permitted 
items in the US, the UK, Japan, France, Germany, Italy, Canada and 








Switzerland (Codex2 or the items which can be checked on its website), 4) 
AHFS, Martindale, Micromedex and etc. the information of the use of the 
medical supplies, 5) the thesis which are published in PubMed, academic 
magazines, the texts which are approved by the related academic associations 
and used by the medical or pharmaceutical universities, 6) the guidance of 
medical examination and treatment which is accredited by the medical 
association, 7) the references (letters) of the actions related to the safety which 
are issued by the MFDS, FDA, Europe EMA, Japan MHLW and other 
medical authorities, 8) the advisory opinions of the central pharmaceutical 
review committee or related academic association’s advisory opinion, 9) the 
references of detailed outlays are provided by the HIRA. The standards of the 
approval for the references of the clinical research are divided into 4 sections 
depending on the research categories: [category 1] the systematic review on 
the subject of the randomly sampled control groups (systematic review, Meta 
analysis), [category 2] the review on the randomly sampled controlled groups 
or the systematic review on the subject of category 3, [category 3] the review 
on the semi-randomly sampled control groups, case control study, cohort 
study, observational and analytic study, [category 4] cross-sectional study, 
before/after study, case report, case series, non-analytic study. The MFDS 
requests the clinical experiment as research to a research institute to prove the 
safety or the effectiveness of the off-label use medications, or advises to add 
the indication for the use of a medicine of the off-label use which is found 
through the clinical experiment. However there is often difficulty in the 
                                                          
2
 Codex including the current year and within 3 years[the US one-PDR, Japan codex, 
the UK one-ABPI DATA SHEET COMPENDIUM, Germany-ROTE LISTE, France-
VIDAL, Italy-L’iniformatore Farma-ceutico, Switzerland-Arzneimittel Kompendium 






clinical experiment, so no progress is made. 
In other countries’ cases of off-label use medications, in the US, 
prescribing medications beyond the limit of the permission is allowed yet the 
entitlement of medical insurance is considered as individually and the safety 
and the effectiveness comes with the doctors’ responsibility. There should be a 
lot of difficulties to enable to use the medication for patients because the 
permission is not made. The pharmaceutical companies cannot market or 
promote the medications as off-label use except the original purpose of the 
use. The pharmaceutical companies should get the permission for the off-label 
use of medication with the clinical experiments after accumulating proven 
cases of the safety and the effectiveness. However realistically because of the 
lack of profit, it is common that pharmaceutical companies avoid this process. 
The American FDA submits a request for clinical experimentation to the 
company; for the medication that causes safety concerns, raising doubts of its 
effectiveness. The FDA actively requests clinical experiments for the off-label 
use medications for the case of rare incurable diseases with no treatments. 
If we look at the medications which are in the process of proving the 
effectiveness of the off-label use medications or already proven clinical 
experiments3, there are 69 cases are in the process or related to Rituximab-
GVHD(Graft-Versus-Host Disease), there are nine clinical experiments 
related to Imatinib-GVHD, and there are five research projects undergoing 
related to Tacrolimus-Vitiligo. Six clinical cases which used Rituximab as a 
treatment have got the results, four clinical experiments related to Imatinib-
GVHD are done and three clinical cases have gotten the result. Two clinical 
experiments related to Tarcrolimus-Vitiligo have been made. The information 








of clinical experiments brought from Clinicaltrials.gov is collected in March, 
2014. Here are frequently used off-label use medications examples; 
Rituximab, Imatinib, Leflunomide, Tarcrolimus, Bortezomib, Erythropoietin, 
Verteporfin, Infliximab, Abciximab, Sirolimus, Etanercept, Deferiprone, 
Misoprostol, Quetiapine, Clonazepam, Mycophenolate, Methotrexate, 
Octreotide, Progesterone, EGF and so on. The FDA made the guideline for the 
use of off-label medications and requests the clinical experiments to the 
pharmaceutical companies or research institutes and if it is possible to do 
clinical experiments the FDA supports them. In England, only the cases 
proved by the prescribers with the evidence or experience for the better 
effectiveness and the safety are allowed to prescribe the off-label use 
medications4 . In Australia, in the guidance of the use of the off-label 
medications, it makes clear that only it is allowed to be used when there is the 
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1.3 The Necessity of Study Using Bioinformatics 
It is essential to have the clinical experimental results on the safety and 
the effectiveness of the off-label use medications. However it is difficult to 
have proper clinical experiments due to the lack of the case numbers because 
most of the cases are either rare diseases or incurable ones. Even though for 
the small size of clinical experiments, it is hard to find the participants and 
also there could be the ethical issue raised related to children patients’ clinical 
experiments. Because of all the practical problems, there are many cases 
which cannot satisfy the requirement of the clinical experiments for the 
permission system therefore the assessment of adequacy of the off-label use 
medications make a judgment relying on the research references which 
provide the basis. If those references satisfy the standards listed above, it does 
not seem to have any big problems. However because actually the ground of 
these references is weak, there needs to be a reasonable alternative. 
One possible alternative is the repositioning of medications. The 
repositioning of medications is the method that newly discovers the 
indications for the use of a medicine by finding out and adding the targets 
which are not intended but discovered. Apart from the expectations, newly 
discovered targets reveal as side-effects or effect on the accompanied diseases. 
For instance, the diabetic treatment, Metformin is used for Polycystic Ovary 
Syndrome which is frequently shown in the patients who have Metabolic 
Syndrome as the off-label use6 (Nathan and Sullivan, 2014) and also used to 
prevent the weight gains caused by intake of psychotropic medicines or as the 
off-label use to treat (Generali and Cada, 2013). In the systematic review and 








the Meta-analysis which is to discover the effectiveness of the off-label use as 
a treatment for the atypical psychotropic medications for adults, because the 
atypical psychotropic medications are often used as the off-label use for 
dementia patients’ anxiety, agitation and obsession, the effectiveness of each 
medication is compared. Among atypical psychotropic medications, 
Quetiapine is effective on the general anxiety disorder and Risperidone and is 
effective on obsession (Maher et al., 2011). Apart from the systematic review 
and the Meta-analysis, the theological method to prove the adequacy of 
effectiveness of the off-label use is needed. 
This paper looks into the methods and the results of studies that try 
new methods to find indications of drugs using bioinformatics. In the research 
which uses the Bioinformatics methods to find the new target of the specific 
existing permitted medications, Xie et. al. (2011) analyzed computer data 
using SMAP(software and web service for binding pocket similarity search 
and polypharmacology) software through the systematic review of the X-ray 
of the  “Nelfinavir binding pocket” of the “HIV protease-1 co-crystallized 
with Nelfinavir” and study of the data bank deposition. The most influential 
“Nelfinavir off-target” is sorted as ABL,  ARK,  AKT2, CDK2, EGFR, 
EPHB4, FAK, FGFR, IGF-1R and PDK1 and with consideration of chemical, 
structural and energy elements, ARK, ATK2, CDK2, EGFR, FAK, IGF-1R 
and PDK1 is considered as the most influential “Nelfinavir off-target”. 
Kinnings et al. (2009) repositioned Parkinson’s treatment, Comtan 
(Substance name: Entacapone) using the chemical system biology for 
Multiple Drug Resistance Tuberculosis. Kinnings, et al. developed the 
approaching method of the Chemical System Biology in order to confirm the 
off-target of the main medications for wide proteome, and in this research, 






Comtan, currently used as Parkinson’s treatment, can be used for tuberculosis 
which has shown resistance to other treatments. This Entacapone, is expected 
to be combined with Enzyme InhA, and directly block the substrate from 
combining. The minimal inhibitory concentration of Entacapone for the 
Tuberculosis bacillus is 260.0 ㎛, which is lower than the concentration that 
shows cytotoxicity for human beings. If the protocol suggested in this 
research be generally applied, the development of the new treatment can be 
accelerated with the guaranteed safety. The research which found the 
medication’s target using the topological character which was analyzed by 
computer after consolidating the functional genomic data among tuberculosis 
bacillus, and generating the functional interactive network offered the 
opportunity of enlarging the potential medication’s target range and the 
opportunity to move to the best target-based strategy (Gaston et al., 2011). 
Bleakley and Yamanishi (2009) find it an amazing challenge to predict 
the accurate, correct and new drug-target interaction under the circumstance 
that there is not much to be discovered in drug-target interaction. Therefore in 
their attempted research, they predict the target protein of given medication 
using “bipartite local model” and then predict the medication for the 
determined protein as the target. For the “drug-target interaction” estimated 
with this method, two independent predictions are possible, and combining 
those two predictions, the prediction of final interaction is individually made. 
With well delivering this suggestion, four classes of the “drug-target 
interaction network”; Enzymes, Ion Channels, GPCRs (G protein coupled 
receptors), and Nuclear receptors are predicted. 
Shigemizu et al. (2012) thinks that already permitted medications could 
be used for the use not intended because with the possibility of processing the 






In the research, the realigned candidate medications which are effective on 
Breast cancer, Myelogenous Vitiligo and Prostate cancer are confirmed. The 
method used and applied here is to find the inverse correlation between the 
‘gene expression level’ which is the most unstable cancer tissue and the ‘gene 
expression level’ which is the most unstable derived by the bioactive 
compounds. With this method, using various ‘gene signature’ they discovered 
the bioactive compounds which control given diseases. This is different from 
the old method which only used the small sized, fixed signature. Candidate 
medications for breast cancer, myelogenou-vitiligo and prostate cancer, 32% 
out of the number of 79, 13% out of 94, 17% out of 88 are FDA approved or 
were suggested in research. It means that this method can be effective in the 
process of finding and developing new treatments and there is a possibility of 
implication for the use of individual custom made medications. 
The individual custom made treatment for cancer patients is getting 
more important. The research for cancer done over centuries shows that the 
molecular biological discovery about carcinogenesis and according to this, 
even the same type of tumor is started by different mutated oncology and can 
react differently to the same treatment (Kim and Han, 2013). Take breast 
cancer as an example of the development of the same and general treatment to 
individual custom made treatment. Dinh et al. (2007) says that the standard of 
choice for the supplemental treatments after the surgery of breast cancer 
shifted from the recurrence risk to the treatment target and reaction. Before 
the early stage of breast cancer patient’s choice of supplemental systematic 
treatment focused on patients, the advantage of supplemental treatment by 
prognosis related to the cancer, and recurrence risk evaluation (Chin et al., 
2006). In other words, as far as the choice of supplemental treatment goes, 






whether it got spread to the lymph was considered as an important element to 
choose the method of chemotherapy and it is closely related to the recurrence 
risk. However after 2005, the treatment reaction element like the hormone 
receptor expression takes an important role in the decision of the 
supplemental treatment. The future treatment is the concept of choice, so the 
treatments are expected to be decided based on the molecule information; the 
molecule subtype of tumor, the result of risk evaluation of Oncotype Dx and 
the prediction result of medication’s reaction and so on. 
The first discovered treatment’s target in breast cancer is the estrogen 
receptor. Tamoxifen is the selective regulator of the receptor; it interrupts the 
chronicle channel which controls the cell division and growth by 
competitively refraining the Estradiol combining with the receptor (Jordan 
and Dowse, 1976). In the 1970s, the Tamoxifen was used non-selectively, and 
it brought about 30% of prognosis improvement (Buzdar and Hortobagy, 
1998). However depending on the revelation of estrogen receptor, when it was 
used on the selected patients, the advantage of Tamoxifen improved up to 
80%. From the early 1990s, as the immunohistochemical staining for estrogen 
receptor was conducted as the required examination, it became the beginning 
of the custom-made treatment (Ravdin et al., 1992; Smith et al., 1987). 
HER2 (Human epidermal growth factor receptor 2) is the receptor 
which takes an important role in cell growth, division and survival as the 
transmembrane glycoprotein of 185 kd. The amplification and over-
expression of HER2 is found in 25~30% of breast cancer patients and it is 
related to the aggressive reveal of tumor, and the bad prognosis (Slamon et al., 
1987). In the 1980s after the humanized monoclonal antibody; Trastuzumab 
which combines with the other domain of HER1 receptor cells being 






released, the innovative development was made in breast cancer treatment. 
They are HERA, NASBP-B31, and NCCTG/N9831. BCIRG 006 and finHER 
trial, and all of them showed the reduction of reoccurrence rate by 39%-50% 
and the reduction of death by 30%(Piccart-Gebhart et al., 2005; Romond et al., 
2005; Tan-Chiu et al., 2005; Slamon et al., 2011; Joensuu et al., 2006; Wang et 
al., 2013). This achievement in the early stage of breast cancer is the biggest 
one after introducing the Tamoxifen for hormone receptor positive patients, 
and this success is the result of selective treatment for chosen patients who 
have the over-expression and amplification of HER2. After this, Lapatinib, 
Pertuzumab, T-DM1(Trastuzumab) which target HER2 show significant 
effectiveness of anticancer, enlarging the selection of treatments for the HER2 
positive cancer patients and make the dramatic improvement of survival rate. 
In the future, the development of biomarkers which are related to the 
activation of P13K channel; the element which is related to the resistance 
toward Trastuzumab PTEN disappearance and PIK3CA mutation will play a 
key role. Through proactive large scale researches, the effectiveness will be 
proved (Wang et al., 2013). 
Since Perou et al. (2000) introduced molecular portrait in breast cancer, 
the importance of molecular subtype is being emphasized more (Paik et al., 
2006), now these luminal A, B, basal-like molecule biological subtype is very 
important in the plan of supplemented systematic treatment. Rather whether 
hormone receptor expression, HER2 and Ki-67 than the size of tumor or the 
spread to lymph become more important and through the use of multi-gene 
assay Oncotype DX or Mammaprint with more accurate indications, the 
supplemented systematic treatment can be chosen after the surgery. Oncotype 
DX introduced in 2006 is the representative custom-made treatment which is 






positive but spread on lymph negative and yet can get the additional 
advantage of chemotherapy on Tamoxifen treatment (Perou et al., 2000). 
Oncotype DX is the indication suggested by The American Society of Clinical 
Oncology (ASCO) 2007, since 2008, The National Comprehensive Cancer 
Network (NCCN) advised to reflect the result of 21 gene RT-PCR assay 
(Oncology DX) based on Category 2B on the decision of supplemented 
treatment for breast cancer patients in its guide line. 
As resistant bacteria appears against the treatment for the disease and 
the multiple drug resistance of the resistance bacteria widely spread all over 
the world, there is a need for the methodology which can verify the reason 
fast and effectively and the inspection method based on the target from 
information of massive compound has used a lot. However without the 
knowledge of the structure of target this method is impossible. On the contrary, 
the entire organism inspection is used more frequently recently because it is 
possible without knowing the target, but time and expense are the elements of 
limitation. The elements of limitation can be avoided by prioritizing the order 
of molecules for the inspection program using a computerized approach. In 
the research of the predictive model for anti-tuberculosis molecule, four 
managed classifiers were conducted in bioassay inspection of three opened 
tuberculosis bacteria inhibitor using the physical-chemical characters of 
compound. Predictive model was confirmed through various statistical means. 
In conclusion, in this research, the target-agnostic predictive model for anti-
tuberculosis treatment is made by applying the machine learning approach for 
analyzing high capacity biological inspection data about anti-tuberculosis 
activities (Periwal et al., 2011). Periwal et al. (2011) made the predictive 
model using the machine learning approach in 2011, in the 2012 research they 






tuberculosis using four supervised classifiers(Naïve Bayer, Random Forest, 
J48 and SMO). It offers 3~4 more strengthened ones rather than randomly 
selected ones.  
The side-effects shown when medications on the market are used 
inform the profile of human-beings’ phenotype. This phenotype information 
sometimes offers additional indication for the use of a medicine for treatment 
of disease. Yang and Agarwal (2011) drew the interrelation between 3175 
side-effects and diseases. This is the result from combining between the 
interrelation of side effect-medication in medication information and 
interrelation of medication-disease in PharmGKB (the Pharmacogenomics 
Knowledgebase). This interrelation, for instance, offered the medication 
realignment theory of “the medication that causes hypoglycemia as a side-
effect could be the potential candidate cure for diabetes”. With the character 
of side-effect, the Naïve Bayes model enables prediction indicators for the use 
of a medicine as a cure for 145 diseases was made. 92% of this model is over 
AUC 0.8 and with extension of this method when it was applied to predict 
new indications for the use of a medicine of clinical compound, 36% of 
suggested model was AUC 0.7. In this research, it is suggested that 
medication realignment should be rationalized based on clinical phenotype 
analysis as well as for the safety evaluation of the harmful effect focusing on 
the side-effects witnessed on clinical trials. 
The research which predicts the combination of medications by 
combining the date of molecule information and pharmaceutical data has been 
done (Zhao et al., 2011). The treatment of combination of medications is a 
good strategy to reduce the side-effects during the treatment of multiple 
diseases and enhance the effectiveness. However screening the completely 






the new computer approach to predict the combination of medications by 
combining molecule and medication data, the method of research is organized 
and expressed by character of the medication’s target or the indications of the 
use of medicine, and if a few of characters are integrated, new characteristic 
forms are found in the combination of already permitted medications. With 
this characteristic pattern, not only it is possible to suggest the combination of 
new medications but also action mechanism of the combination of 
medications can be explained. 69% of top rank in the predicted combination 
of medications is proved by researches and the rest of the combination of 
medications is suggested that it has the possibility of new combination of 
medications. 
There was research which attempted the huge scale docking of small 
molecule medication corresponding to medication target protein in computer 
approach research which seeks the new target out of existing medications (Li 
et al., 2011). As the result of attempting, the relation map of medication-target 
interrelation interval was obtained and the new interrelation was found. The 
method used here focused on removing the false positive interrelation 
prediction by setting up the standard using the matched score with the already 
known interrelation docking and the specialty. The database accumulated in 
this way contains 252 of human target protein and 4621 of already permitted 
or experimental small molecule target out of Drug Bank. By crossing over 
docking and screening by the strict score, the top medication-target 
interrelation was selected. The proven fact through is that Nilotinib is a strong 
MAPK14 inhibitor and it suggests that this medication can be used for 
infectious diseases. 
In the published research, the predicted interrelations of top 31 






study method is considered to expect to use this approach. Newly discovered 
interrelation enables us to realign the applied medication as the off-target 
related disease treatment, to reveal the mechanism of drug action and to 
understand the side-effects. Polypharmacy means medicating many 
medications all at the same time and it is the treatment which combines 
functionally non-related medications; this is to prevent the drug resistance 
which could be caused when the medication is selectively effective on only 
one ligand and polypharmacology is being used with the expectation of more 
than one effect with one medication using the fact that one medication has 
more than one target and many mechanism of drug actions. The researches 
which believe that focusing on polypharmacology will open the future of 
treatment development are being actively conducted. 
Recently in spite of the amazing scientific development and investing a 
lot on a R&D, newly developed medications often disappear from the 
pharmaceutical market after being launched because of the side-effects or the 
safety issues. Drug molecules cause polypharmacology to often interact with 
other targets and when the interrelation with unintended target expresses, it 
appears as side-effect. Polypharmacology became one of the prominent 
challenges in drug development (Reddy and Zhang, 2013). This challenge is 
seen as the opportunity to find a reasonably developed way for effective and 
safe treatments. Although polypharmacology is important in medication 
development and discovering, it is difficult to completely review all of the 
targets in the applied range with experimental ways. The most possible way is 
to use omics (proteomics, cheminformatics) technologies (Schmid and Blank, 
2010; Joyce and Palsson, 2006). The purpose of using the method of 
polypharmacology is to find not-known off-target in existing medications 






approach needs to integrate computer plan, chemical compound, inside 
laboratory biological pharmaceutical experiment and clinical experimental 
from different regulation systems (Yamanishi et al., 2008; Dar et al., 2012). 
With the basics of chemical similarity, in the new study which predicts new 
indications for the use of a medicine and unknown side-effects (Keiser et al., 
2009) identify new target with ligand and compared 3665 medications which 
respond to hundreds of targets and  were permitted by the FDA and the 
medication under experiment. The chemical similarity between medications 
and ligand enables to predict thousands of unexpected connections. Overall 23 
new targets were confirmed and five of them seem very pursuable. 
Understanding, knowledge and prediction of off-target can be a reasonable 
approach to understand side-effects (Echiborn, 2011). In this study which 
provides information of 25,000 medications including the ones now off the 
market because of side-effects or under experiment, the network is made from 
publicly available information which was collected and edited; about 21,500 
of interrelation between medications and 104,000 protein; interrelation protein 
and protein based on this network, realignment of medications could be 
started. The network, named “PROMISCUOUS” is publicly available. 
The methods to reposition medications used in bioinformatics take 
other off-target from publicly opened databases along with the medications 
known to have permission and getting indications for the use of a medicine 
and use the off-target as main target to figure out if the medications which 
have indications for the use of a medicine can be used for other use. The 
general method is to find out the genes which are related to diseases using the 
genetic information and search the medication which targets the genetic 
protein. Without any start initiation of disease or medication, aimlessly 






all the diseases can be progressed. Because of the time limit, the size of scale 
is needed. Therefore in many cases of the study for repositioning of 
medications, it starts with the medications for diseases which draw social 
attention or issues limitedly. 
GenBank which provides genetic information publicly is a genome 
sequence database provided by the NCBI (National Centre for Biotechnology 
Information), NCIBI is the subsidiary organization of NIH and at the same 
time it is part of The International Nucleotide Sequence Database 
Collaboration. This united DB is consists of the information of the DNA 
DataBank of Japan (DDBJ), the European Molecular Biology Laboratory 
(EMBL) and GenBank at NCBI. The information of these three organizations 
is updated on daily basis. The information of the sequences of over 100,000 
creatures has been gathered for over 30 years and this information is used to 
provide the DB with the basics for researching, comparing and predicting 
sequence and structure of DNA or protein of creatures by biologists. The 
NDBI BLAST program is usually used to search gene information, and 
includes sequences of other than type strain compare to commercially paid 
DB yet it is less refined and limited for providing related sequence 
(Wikipedia). In the research by Park et. al, they analyzed making connections 
with other opened DB like GenBank, EzTaxon and BIBI and the results 
showed that analyses performed using GenBank combined with EzTaxon 
were more discriminative (Park et. al., 2012). 
Genotator is an open access in http://genotator.hms.harvard.edu for 
academic study and it provides the interrelation of relation between genes and 
diseases. It organized the number of genes in order depending on how 
relevant the interrelation; by combining data from other areas or taking gene 






TKperl, it uses sequence analyzing program. The sequence analyzing program 
is divided into three areas; gene finder (Genie, GRAIL, GeneFinder, xpound, 
GeneMark), database homology searches (BLASTN, BLASTX), sequence 
feature predictors (start/stop codons, open reading frames, promoters, splice 
sites, tRNA genes). Front end is written in perl and TKperl and uses Gregg 
Helt’s bioTKperl widgets. It was developed by SUN (Sun Microsystems, Inc) 
and installed by SGI (Silicon Graphics International) and DEC (Digital 
Equipment Corporation) alphas. Because Genotator is not only a commentary 
method but also easy to use, free and provides the source, it can be 
manipulated depending on researchers’ needs (Harris, 1997). The website, 
Genotator.hms.harvard.edu was operated by the Harvard Medical School Wall 
lab. Then its ownership changed over to Stanford Medical School and 
https://wall-lab.standford.edu/ was in management, but today 2014, 
September when it will re-open or operate is unknown.  Figure 1.1 makes it 
easy to understand of algorithm of Genotator (Wall et al., 2010). Scoring 
formula which makes it quantified about the interrelation between gene and 
disease in Genotator below. 
Y=X1-X2+φX3+1/γX4+1/κX5 
Where, Y is Genotator score (GS), X1 is the score of gene-disease 
association in genetic association database (GAD), X2 is the score of none 
gene-disease association, X3 is gene prospector’s score of gene-disease 
association (GPS), X4 is DB score from all 11 database which shows genetic 
information, and X5 is the number of references to provide genetic 
information. The constant, φ, γ, κ are used to give weights to GPS, DB, REF 
and overall it is best performed when 100,10,5 are used. In the research of 






and X5 as REF. Thus, 
GS=GADＹ- GADＮ+φ(GPS)+1/γ(DB)+1/κ(REF), 
Where, 
GADＹ = Total number of “Yes” labeled associations for the gene and 
disease in the Genetic Association Database 
GADＮ = Total number of “No” labeled associations for the gene and 
disease in the Genetic Association Database  
GPS = Gene Prospector’Ss score of gene-disease association 
DB = Number of total databases (out of 11) that the gene appeared in 
REF = Number of total references for the given gene 
According to Genotator algorithm, the characters are collected from 
databases such as GAD, Gene prospector (HuGE navigator) and NCBI and 
depending on the contribution, relation score is calculated following the 
scoring algorithm. 
The DB provided in Genetator are 11: GeneCards, Genetic Association 
database, HuGE Navigator, Human Gene Mutation Database, Online 
mendelian Inheritance in Man, Your Favorite Gene, UniProt, PharmGKB, 
Entrez Gene, WikiGenes and GenAtlas. The special information from the DB 
is list of genes, relation with diseases, p-value (from genome wide association 
studies), Gene Prospector Score, List of Pubmed References, official full 
name, symbol synonyms, chromosome Number, location on chromosome, 
gene ID and Ensemle ID. Wall et al. (2010) who are responsible and operate 
Genotator site confirm that after examining the accuracy of information 
provided by Genetator about Autism Spectrum Disorder (ASD), Parkinsons’s 






between gene and disease, individually 75%, 60%, 75% match the list of gene 
and high ranking order in other references and DB. The programming word 
used is JAVA and Python and can be downloaded as the information of gene 
in the format of FASTA. In Genetator, the specific information about disease 
can be learned with interrelation score, so when it comes to treatment, the 
effectiveness of mediations can be proved more than before. 
Some DB use the methods from the researches that sample the 
information needed, find out off-target and suggest realignment of medication. 
In the case of analyzing the protein of creature with computer and confirming 
the medication target with topological character in network, the united 
functional interrelation network is provided by STRINGS (the Search Tool for 
the Retrieval of Interacting Genes/Proteins) DB. To find out the target with 
the similarity of ligand, the target is compared using BLAST algorism and 
Baysian classifiers with the predicted score by SEA (similarity ensemble 
approach). Confirm medication-target predicted in MDDR (MDL Drug Data 
Report) and WOMBAT (the World of Molecular Bioactivity) DB, and new 
medication repositioning which is not in DB can be suggested. The 
information of genes which can be downloaded in XML format is analyzed 
using LingPipe-package or text-index is made using Lucene package provided 
Apache Software Foundation. In the software, Cytoscape, which visualize 
network, general formats like XGMML or SBML are used. When certain 
medication is given, the method to predict the target protein is SLMs 
(bipartite local models). This method predicts the given medications first and 
predicts the medications targeting the given protein: after individually predicts 
and then make a network and confirm the medication-target in the network. 
Another method which compares the accuracy for predicting target is KRM 






neighbor) algorism. With BLMs, a few medications can be chosen to practice 
experimentally. 
Generally bioinformatics methodology compares sequence or structure 
similarity using information of genes analyzed from DB. The next step for 
this method, the attempt of realigning existing medications for the new use is 
based on DB and uses the software is organized up to the purpose. 
http://bioinformatics.charite.de/promiscuous/ an open-access and free website 
makes network based on structural similarity of medications and enables to 
use network-based approach as the starting point of medication realignment. 
Using this website enables to make interrelation network with medication, 
target and pathway. Genotator mentioned above is meta-database and because 
it provides the whole lists of diseases-genes interrelation, gene mediated 
medications realignment can be tried-out. This is a two-step method, first get 
the genes related to two diseases from Genotator, find the shared (common) 
gene and then make protein-protein interaction network. As the next step, get 
the information of medications as treatments for two diseases from DrugBank. 
With this information, make drug-similarity network. If the target shared 
between medications, structural similarity, has similar side-effects or having 
the interrelation with same medications, those medications have a lot in 
common can be considered as treatments for different diseases. When the 
study of medications realignment is started, with the clients who had clinical 
experiment, look for the treatments for the diseases which have no cure and 
with pharmaceutical companies for developing new products, try to realign 
the medications first which have accumulated information and side-effects. 
One type of medication realignments is off-target use of drugs and the 
method of confirming the safety and effectiveness with general 






The difference is that it starts from the medications which have been used for 
a while. The way of confirming the adequacy of off-target use of drugs and 
the way of medication realignments are the same, yet off-target use of drugs 
have been somewhat proved for the side-effects and effectiveness in 
references or clinical trials. There are many studies which try to find the new 
indications for the use of a medicine with certain characters from existing 
medications are under progress and the methodology of these studies is 
studied and provided. In this study, using Genotator which provides overall 
information of genes organized from DB, the information of genes for the rare 
incurable diseases which do not have cure will be described. By revealing off-
targets other than permitted off-targets for off-target use of drugs used with 
some basics, the effect revelation should be explained and additional side-
















Figure 1.1 Genotator algorithm. This figure describes how Genotator works. When 
user enters a disease term, gene information is gathered from 11 database and 
overlapping terms are deleted and organized. Then, standardization and calculation of 
association score are carried out based on the information collected from GAD, Gene, 
Gene Prospector (from HuGE Navigator), and NCBI. (Wall et al. BMC Medical 













1.4 The Purpose of Study 
The objective of this study is to provide evidence for the safety and 
effectiveness of agents that are currently being used for off-label indications. 
The method of finding new targets other than the targets known in existing 
medications is prevailed in bioinformatics and there have been results in many 
medications. The genes which are related to target protein of medications-
diseases are being known and as the differences in reaction to treatments 
depending on difference of individual genes draw attention, many studies 
about custom-made treatment are prevailed. Currently using the medications 
differently from the permitted contents is taken place a lot in cancer treatment. 
For instance, as the examination of genes of patients who have lung cancer or 
colon cancer is expected to EGFR mutation, ALK merge genes and KRAS 
mutation, it is used when there is no effect on specific cancer treatment. If the 
mutation is confirmed in the experiment of genes, the effectiveness of 
treatment can be improved by using other anti-cancer treatments. Breast 
cancer is one of the cancers which have a well-known genetic factor, 5~10% 
of patients are familial breast cancer patients. It is well known that the 
mutation of BRCA1, BRCA2 and p53 can cause breast cancer7. When the 
treatment method is decided for breast cancer patients, based on the medical 
basics from references as the basic treatment, the molecular and biological 
characters of breast cancer should be considered (Oh, 2012). The most 
important thing is to confirm the revelation of hormone receptor and over-
revelation of human epidermal growth factor receptor 2 (HER2) protein, 
depending on this, supplementary chemotherapy and metastatic cancer 
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chemotherapy are decided. Especially about 20% of breast cancer patients 
over-reveal HER2 protein, and those who over-reveal HER2 protein are 
reported to have bad prognosis compare to others who don’t have (Slamon et 
al., 1987), the possibility of target treatment was suggested for this, in 1998 as 
humanized monoclonal antibody Trastuzumab which target extracellular 
domain of HER2 protein was developed, the improved result of treatment was 
reported in metastatic breast cancer when HER 2 is revealed compared to the 
previous treatment with chemotherapy only(Slamon et al., 2001). This 
development of target treatment became a turning point in breast cancer, and 
is one of the most important parts in treatment. 
As the researches that the target protein of many medications used as 
off-target use of drugs is connected to not only the gene related to one disease 
but also related to other diseases have been done, existing medications can be 
used as new treatments within a short time. The most appropriate way is to 
sample the information needed from big data using computer approach in 
order to use the massive information of genes and medication accumulated for 
the development of the new indications for the use of a medicine. In this study, 
I try to show the logical possibility of using the same medications for different 
diseases by making network of genes sampled from Genotator and DrugBank 
and genes shared in this network as mediator. 
There are cases were not permitted in this way yet used but now as a 
result of clinical experiment, the new indications for the use of a medicine are 
added. The biological product, Rituximab is one of examples. Early 
Rituximab was limited to Non-Hodgkin’s Lymphoma: NHL as permitted 
indications for the use of a medicine in 1997 and in 2006, Rheumatoid 
Arthritis: RA and in 2010, Chronic Lymphocytic Vitiligo: CLL are added. In 






Granulomatosis with polyangiitis; GPA) among 85% of patients, as 
Antineutrophil Cytoplasmic Antibodies; ANCA is proved as an autoimmune 
disease with positive reaction, is has been used as off-target use and in 2011 
April based on the clinical experiment it got additional indications for the use 
of a medicine (Falk et al., 2011). Anti-neutrophil cell cytoplasm anti-body and 
ANCA are the anti-bodies highly related to ANCA-associated vasculitis; GPA, 
Microscopic polyangiitis; MPA and Churg-Strauss syndrome. 70% in MPA 
and 50% in Churg-Strauss syndrome, it shows relation 8 . In these rare 
incurable diseases, if the mechanism of outbreak can be studied and revealed 
from the point of view of the molecular biological, the development or 
discovering of treatment will be accelerated. There are cases of the use except 
the original use is applied for the experimental purpose or when treatments are 
not working. 
In French national institute of health and medical research, as the result 
of applying Rituximab to the patients who have Pemphigus, 59% out of 
treated patients could live without symptoms for 6 years (Colliou et al., 2013). 
However Roche, the pharmaceutical company, has no plan to apply for the 
approval as a treatment for Pemphigus. This company also doesn’t encourage 
the use of Rituximab as off-label use for Pemphigus although they 
acknowledge that it has been prescribed9. Although Roche does not consider 
adding indications for the use of a medicine because of its lack of actual 
profit; Pemphigus is a rare autoimmune disease happening 7 in 1,000,000, 













because in the field only treatment is steroid and immune restrainer as 
supplement and it has high rate of re-occurrence with severe side-effects, 
there should be substitute medications. Since there are references showing 
that Rituximab is effective on Pemphigus as off-label use (Cianchini et al., 
2007; Ahmed et al., 2006) and target protein is shared as common, there is a 
theological reason of use as off-target use of drugs(Feldman and Ahmed, 
2011; Muller et al., 2010). When there are no treatments at all or treatments 
which cause severe side-effects, there should be replaceable treatments. 
Therefore there needs to be support and encouragement from government for 
clinical experiments and researches for the pharmaceutical companies which 
pursue economical profit. 
Medication realignment using bioinformatics compares the degree of 
instability in disease-associated genes to medication destabilized genes. In this 
study, it will be shown that based on the medications which registered and 
used for off-label use at MFDS and their use, after pairing up original applied 
diseases and off-label use of drugs, find the common genes, analyze the level 
of relation of genes with STRING, find medications’ target, structure, 
medication interrelation and side-effects and then make network about 
similarity of medication and if there are more than two common parts in this 
network, there would be the same indications for the use of medicine between 
medications. The hope for this study is that it would be used as one of 








CHAPTER II. MATERIALS AND METHODS 
 
 
2.1 Protein-Protein Interaction Network Based 
Research using STRING  
 
There are many ways to systematic repositioning of medications. The 
candidate medication can be round in the similarity of diseases or it can be 
started with hypothetical assumption that similar medications would be 
effective on the same diseases. For instance, the medications which show the 
same side-effects would commonly effect on one disease. However these 
researches have not been proved right yet. The purpose of this study is to find 
the repositioning of off-label use have been used and new indications for the 
use of a medicine using the method of repositioning of medications. Two 
diseases which show the similarity in pre-outbreak are chosen, and get the 
information of related genes for each disease from Genotator. The list of 
genes which is needed first out of the information of genes in FASTA format 
is, organized separately. The shared genes between the diseases which have 
too many lists of related genes and the diseases which don’t have genes well-
known are chosen up to the relation score 1.00 to compare only the similar 
relation level. The interrelation of protein between the shared genes is from 
STRING DB. STRING shows both directly related interrelation and 
functional indirectly related interrelation and refer to four DB; Genomic 
Context, High-throughput Experiments, Co-expressions and Previous 






species of creature. The common genes in paired diseases can be drawn as 
interrelation network between protein-protein by adopting “Search by name” 
in STRING. In the past, the data reference obtained by adopting the 
information of genes was saved on http://string-db.org; after signing on, go to 
my data and then the applied date and interrelation between protein-protein 
networks. In the united network, the bold line means strong relation when it is 
shown with confidence view and the lines of different colors show the type of 
references which prove the relation. This is the form of summary for 6 of 
protein-protein interrelation network which are analyzed the interrelation with 
finding the common genes in 6 paired diseases (Figure 3.1~3.6). Then get the 
information about medications used as treatments for the diseases as a pair 
from DrugBank, the drug database. In the first stage, if the target of 
medication is related to protein-protein interrelation network, that medication 
can be the candidate of realignment medications which will have new 
indications for the use of a medicine. However there are targets which are not 
known yet, in the second stage, based on the similarities of the treatment 
drugs prescribed for the diseases, the possibility of medication realignment 
will be examined. 
As the first step, the genes which related to the diseases from an open-
access information meta-database and Genotator10 are taken. The information 
of genes can be downloaded in FASTA format at Genotator. A few types of 
diseases are classified by comparing the off-label use drugs and the permitted 
indications for the use of that medication. Genotator calculates the score 
depending on the possibility of relation of genes related to the individual 
disease. Because there are many diseases which have no related genes 








discovered, while there are too many genes related to some diseases, to make 
it more effective and look in details, the genes which were calculated the 
scoring up to 1 by Genotator are chosen to make protein-protein interaction 
network. The genes of diseases which are under registration progress at 
MFDS to use existing medications as off-label use drugs because there is no 
treatment or non-acceptance are collected first. Then the common genes the 
pair of the medication between as the permitted indications for the use of 
medicine and the off-label use for the disease are looked for. The process of 
finding genes related to diseases, paring the diseases seems to have possibility 
of relation and finding the common genes is shown as Figure 2.1 and Figure 
2.2. 
Hypertension-Wegener, Panic disorder-Alzheimer, Albinism-
Melanoma, Hypertension-ARDS(Acute Respiratory Distress Syndrome), 
Schizophrenia-Panic disorder, and Tourette syndrome-Schizophrenia are 
paired with under the supposition that they have many common genes related 
to diseases. The analyzing relation between shared genes in common is done 
by STRING11. The information of target protein about treatment for the 
diseases listed above is from DrugBank12. The first stage is that once the 
target protein of medication which cures either of disease out of paired 
diseases is confirmed at protein-protein interrelation network, the medication 
can be used for the other disease out of paired diseases. 
The second stage is to suppose (reason) based on the similarity 
between candidate medications which will be repositioned. Because not all 
the target protein of medications is discovered, this process is necessary. The 










target protein of medication, side-effects, the structure of medication and the 
information of medication interrelation are from DrugBank. DrugBank 
provides the information of 1558 of medications. 155 of biotech medications 
and 4200 of medication targets (Version 4.0). The treatments for 6 pair of 
diseases can be searched with the name of disease on Medscape.com and 
make the list of the medications for treatment or can be searched with the 
name of medication as off-label use and confirm off-label indication. Since 
this process should be done manually, the medications should be limited as a 



















2.2 Drug-similarity Network based Research using 
Cytoscape 
 
The information of the medications as treatment for 6 paired diseases is 
from DrugBank. This process should be done manually so heterogeneous 
information is united into consensus terminologies as possible and the 
descriptive letters are translated into simple terms. For instance, the side-
effect expressed as sleep disorder, insomnia, sleep disturbance or trouble with 
sleeping is united as sleep disorder and the one expressed as tightness in the 
chest, chest pain, chest pain or discomfort or chest tightness is united as chest 
pain. The information is about the target of medication, medication 
interrelation, the substructure of medication and the side-effects of medication, 
and the drug-similarity network is made using the information collected for 
the treatments prescribed for the disease. Figure 2.3 shows the list of 
medication targets are from DrugBank and organized. The node that can be 
seen in medication-similarity network is the cases that there are shared 
proteins between the medications, the similarity of medication structure, same 
side-effects or shared interrelation medications. If less than two nodes are not 
overlapped, it will be excluded from the candidate medications of 
repositioning medications. The reason is that the various structures of 
individual medication are limited to basic structure, and because there seem to 
have too many medications which have the same structure, only when they 
have something in common other than the basic structure it seems possible to 
realign medications. Especially having the shared related genes in paired 
diseases as the target, the medication has similar side-effects is the proof of 






drawing using Cytoscape 13 . The process of making the drug-similarity 
network is shown in Figure 2.4 from a to f in order. 
Among the medications used for Hypertension-Wegener 
Granulomatosis paired diseases, Rituximab was the permitted treatment for 
anticancer and arthritis, it has been used as off-label for Wegener 
Granulomatosis and it got permitted in 2011. Bring in the DrugBank structure 
of the peptide for Rituximab and another couple of drugs, and put it in Figure 
3.7~ 3.11 to show the correlation of structure and function. The target of 
Rituximab is MS4A1 and the drugs causing an interaction mediated by the 
target are Ibritumomab, Obinutuzumab, Tositumomab. The targets of 
Rituximab are 12 (MS4A1, FCGR3B, C1R, C1QA, C1QB, C1QC, FCGR3A, 
C1S, FCGR1A, FCGR2A, FCGR2B, FCGR2C) and Ibritumomab has the 
same target. The two drugs are not the same in structure. MS4A1 is the only 
target of Obinutuzumab and has relatively less side effects than the other three 
drugs. The targets of Tositumomab are 11(MS4A1, FCGR3B, C1R, C1QA, 
C1QB, C1QC, FCGR3A, FCGR1A, FCGR2A, FCGR2B, FCGR2C), 
comparing to Rituximab, only CIS is excluded. So the difference of side 
effects compared, Hypotension, Vasodilatation, Hypothyroidism, Peripheral 
edema, Myalgia, Arthralgia, Pharyngitis, Dyspnea, Rhinitis, Pneumonia, etc. 
appear in only Tositumomab and the type or frequency of other side effects 
are much less expressed. In 4 drugs of MS4A1 target, bleeding gums, blood in 
the urine or stools are caused by Rituximab, Ibritumomab, Obinutuzumab and 
nausea and vomiting, back pain are caused by all 4 of them. Rituximab, 
Obinutuzumab and Tositumomab have a common interaction with other anti-
cancer is Trastuzumab. 








The targets of Trastuzmab are 13 (ERBB2, EGFR, C1R, C1QA, C1QB, 
C1QC, C1S, FCGR1A, FCGR2A, FCGR2B, FCGR2C, FCGR3B, FCGR3A), 
except for ERBB2 and EGFR, 9 targets are the same with the targets of 
Rituximab, Ibritumomab, Tositumomab and C1S is consistent with the target 
as the target of Rituximab and  Ibritumomab. Drugs that target the shared 
gene, TNF on HTN-WG is seven; Etanercept, Adalimumab, Infliximab, 
Golimumab, Certolizumab, Pomalidomide, Amrinone and the drug which is 
licensed in rheumatoid arthritis and psoriasis are Etanercept, and it is used as 
off-label use for vasculitis, granulomatosis and even for alzheimer disease. All 
the targets of Etanercept are 14 besides TNF; TNFRSF1B, FCGR1A, 
FCGR3A, FCGR2A, FCGR2B, FCGR2C, LTA, FCGR3B, C1S, C1R, C1QA, 
C1QB, C1QC. Etanercept’s side effects are chills, cough, fever, sneezing, sore 
throat, congestion in the chest, depression, fast heartbeat, frequent or painful 
urination, itching, pain, redness, or swelling on the skin, joint or muscle 
stiffness, tightness, or rigidity, shortness of breath, stomach discomfort or pain, 
and so on. Drugs that cause interactions are tofacitinib, trastuzumab and 
rilonacept. Other 3 drugs that target the TNF are infliximab, golimumab, 
certolizumab known as having only a single target. The drugs which have 
interactions with infliximab are Golimumab, rilonacept, tofacitinib, and 
trastuzumab. Side effects are abdominal or stomach pain, chest pain, chills, 
cough, dizziness, fainting, fever, flushing of the face, headache, hives, itching, 
muscle pain, nasal congestion, nausea, runny nose, sneezing, sore throat, 
tightness in the chest, troubled breathing, unusual tiredness or weakness, 
vomiting and so on. 
The drugs which cause an interaction with Golimumab are abatacept, 
anakinra, belimumab, canakinumab, certolizumab, infliximab, natalizumab, 






possible side effects are body aches or pain, chills, cough, difficulty with 
breathing, ear congestion, fever, headache, loss of voice, muscle aches, 
sneezing, sore throat, stuffy or runny nose, unusual tiredness or weakness, and 
the like. Certolizumab has an interaction with abatacept, anakinra, golimumab, 
natalizumab, rituximab and tofacitinib and the side effects are bladder pain, 
bloody or cloudy urine, body aches or pain, chills, cough or hoarseness, 
difficult, burning, or painful urination, difficulty with breathing, ear 
congestion, fever, frequent urge to urinate, headache, loss of voice, lower back 
or side pain, nasal congestion, runny nose, sneezing, sore throat, unusual 
tiredness or weakness and so on. In addition to TNF, there are 11 more targets 
of Adalimumab; FCGR3B, C1R, C1QA, C1QB, C1QC, FCGR3A, C1S, 
FCGR1A, FCGR2A, FCGR2B and FCGR2C and the drugs that have an 
interaction with are canakinumab, rilonacept, tofacitinib and trastuzumab. As 
side effects, abdominal or stomach fullness, body aches or pain, cough or 
hoarseness, ear congestion, gas with abdominal or stomach pain, 
lightheadedness, loss of voice, lower back or side pain, muscle aches and 
pains, nasal congestion, pain or tenderness around the eyes or cheekbones, 
rapid and sometimes shallow breathing, shivering, sunken eyes, thirst, trouble 
sleeping, warmth on the skin and wrinkled skin can be shown. 
Pomalidomide has 3 targets, the protein cereblon, TNF and PTGS2 and 
can have an drug interaction with ketoconazole, rifampicin and the side 
effects appear to be in the abdominal or stomach pain, black, tarry stools, 
bladder pain, bleeding gums, bloating or swelling of the face, arms, hands, 
lower legs, or feet, blood in the urine or stools, bloody nose, body aches or 
pain, burning, numbness, tingling, or painful sensations, chest pain, chills, 
cloudy urine, confusion, constipation, cough, decreased or increased urination, 






dizziness, dry mouth, ear congestion, fast or irregular heartbeat, fever, 
frequent urge to urinate, headache, incoherent speech, increased thirst, loss of 
appetite, loss of voice, lower back or side pain, metallic taste, muscle pain or 
cramps, muscle weakness, nasal congestion, nausea or vomiting, numbness or 
tingling in the hands, feet, or lips, pain, pale skin, pinpoint red spots on the 
skin, rapid weight gain, runny nose, shakiness in the legs, arms, hands, or feet, 
sneezing, sore throat, tightness in the chest, trembling or shaking of the hands 
or feet, troubled breathing with exertion, ulcers, sores , or white spots in the 
mouth, unsteadiness or awkwardness, unusual bleeding or bruising, unusual 
weight gain or loss, weakness in the arms, hands, legs, or feet, and the like. 
Amrinone has the bipyridines and oligopyridines structure and its 
targets are PDE3A, DE4B, TNF and PDE3. The side effects are 
thrombocytopenia, nausea, diarrhea, hepatotoxicity and arrhythmias. It will be 
determined the effectiveness and safety of off-label use for Wegener's 
granulomatosis by obtaining the drug-similarity network of the drugs that 
target TNF and the ones targeting MS4A1 known on paired disease, 
Hypertension-Wegener Granulomatosis. Rituximab in Wegener 
granulomatosis has already been granted a permit an also be used for 
etanercept or infliximab as off-label. 
 In Panic disorder- Alzheimer disease pair, there are 24 shared genes 
and drugs that target the HTR2A worth considering realignment medications 
are donepezil, paroxetine and desipramine, so the drugs-similarity network of 
these medications is made. Some the drugs used for panic disorder or 
Alzheimer targeting CHRNA7 CHRNB2 is Gabapentine and Gabapentine and 
Memantine are 2 drugs that target GRIN2B. Paroxetine, Donepezil and 
Desipramine are the drugs that targets the HTR2A and the drugs that target 






drugs that target MAOA are Tranylcypromine and Sertraline and the drugs 
that target SLC6A4 are 12 (Fluvoxamine, citalopram, venlafaxine, 
imipramine, fluoxetine, trazodone, paroxetine, sertraline, desipramine, 
escitalopram, clomipramine). It appears the drugs that target the HTR2A have 
possibility of other uses, donepezil and paroxetine from the drugs, donepezil, 
paroxetine and desipramine that used for panic disorder and alzheimer have 
common in piperidine structure and the drugs that cause an interaction with all 
three in common are isocarboxazid, moclobemide, phenelzine, tolterodine, 
tranylcypromine, trazodone, trimipramine, triprolidine and zuclopenthiol and 
the drugs which have an interaction with only donepezil and paroxetine are 4; 
mesoridazine, pimozide, risperidone and thioridazine. The drugs that have an 
interaction only with paroxetine and desipramine are 11; desvenlafaxine, 
galantamine, phenylpropanolamine, rasagiline, sibutramine, tamoxifen, 
tamsulosin, terbinafine, tramadol, venlafaxine and zolmitriptan. The drugs 
that have an interaction with donepesial and despramine are 5; cimetidine, 
quinidine, thiothixene, trospium and ziprasidone. Vomiting, loss of appetite, 
muscle cramps, muscle and blurred vision as side effects of this is expressed 
in common. 
The common genes in Hypertension-Acute Respiratory Distress 
Syndrome (ARDS) disease pair are 22 but there is no special treatment of 
ARDS. The treatment for blood pressure -pril targeting the common gene, 
ACE of paired diseases can be considered to be as realignment medications 
and there is a necessary to examine Drotrecogin alfa which targets CLACA 
along with glutathione which targets GSTM1 or GSTP1. However because 
ARDS is a serious medical condition that threatens the life, the treatment for 
this is different from the purpose of the drugs which examined the 






suggestion of realignment medication by making drugs-similarity network. 
The shared genes in Schizophrenia-Panic Disorder disease pair are 86 
and the drugs that target CHRM1 in shared genes used for Schisoperenia or 
panic disorder are 12(chlorpromazine, loxapine, aripiprazole, clozapine, 
olanzapine, quetiapine, ziprasidone, paroxetine, citalopram, escitalopram, 
imipramine and desipramine) and the possibility of realignment will be 
approached through the drug similarity network. Drugs having a common 
target, HTR2C are all of 9 except paroxetine, citalopram and escitalopram the 
drugs that target SLC6A4 are 6; loxapine, paroxetine, citalopram, 
escitalopram, imipramine, desipramine. The side effects can be shown in 
common are convulsions, fast heartbeat or irregular pulse, sore throat, 
dizziness or fainting, blurred vision, Agitation, Abdominal or stomach pain, 
muscle spasms or jerking of all extremities, yellow eyes or skin and the drugs 
show loss of appetite are paroxetine, citalopram and desipramnine, the drugs 
show weight loss are paroxetine, citalopram and imipramine. The drugs have 
dibenzazepines structurally are lozapine, clozapine and quetiapine and the 
drugs with dibenzazepines structure are imipramine and desipramine. 
By collecting the information of the medications for Schizophrenia and 
ones for Tourette syndrome from DrugBank, drugs-similarity network is made 
using the information about structure, targets, interaction, side-effects of 
commonly shared 5 medications (Fluphenazine, Haloperidol, Olanzapine, 
Risperidone, Ziprasidone). Although Haloperidol is the only permitted 
medication for Tourette syndrome and Schizophrenia, the safety-effectiveness 
of other 4 drugs as off-label will be confirmed. Tourette syndrome and 
Schizophrenia are suitable to prove the adequacy of using as off-label use 
because they have 25 shared genes which is easy to compare relatively and 






drugs which are used for Tourette syndrome and Schizophrenia, Haloperidol 
has phenyl-piperidine-butyrophenone structure and the targets are 5; D(2) 
dopamine receptor, D(1A) dopamine receptor, Glutamate receptor inotropic, 
NMDA 2B, 5-hydroxytryptamine receptor 2A, D(3) dopamine receptor. The 
shared targets between drug targets and the shared targets in paired diseases 
are 3; DRD2, DRD3, 5-hydroxytryptamine receptor 2A (HTR2A) and there 
are 10 including that are being tested or withdrawn and 5 of them are being 
allowed to use as drugs. The drugs that have an interaction with haloperidol 
are 3; trihexyphenidyl, tridihexethyl, procyclidine. The side effects of 
haloperidol is QT prolongation (CV), EPS, TD, NMS, including blood-related 
or more. 
The fluphenazine has phenothiazine structure with 3 targets, DRD2, 
DR1A, calmodulin and shares two common targets, DRD2 and DR1A with 
haloperidol, and has a common target, DRD2 with the paired disease, 
Schizophrenia-Tourette. 19 out of 21 structure similar drugs are permitted to 
be used, and DRD2-mediated interactions between medication are 8; haldol, 
olanzapine, risperidone, ziprasidone and structure similar drugs; 
trifluoperazine, trifluopromazine, prochlorperazine, promethazine, 
chlorpromazine, thioridazine, thioproperazine and methotrimeprazine. 
Stuructuer smilar drugs causing calmodulin-mediated interaction are 2 of 
them; promethazine and trifluoperazine. The drug interaction DR1A-mediated 
is haldol, olanzapine, risperidone and ziprasidone and 7 from structure 
similarity drugs are chlorpromazine, methotrimeprazine, promazine, 
propiomazine, thioridazine, trioproperazine and trifluopromazine. The 
fluphenazine’s side effects are Tardive Diskinesia (TD), Extrapyramidal 
Symptom (EPS), Neuroleptic Malignant Syndrome (NMS), blood pressure 






women, edema, weight changes, milk secretion and so on. 
The structure of Olanzapine is benzodiazepine and has one structure 
similar drug, clozapine with 34 targets and 10 of interaction drugs but there is 
nothing in common with target-mediator or structure similarity drugs. The 
common targets with the paired diseases, Tourette syndrome –Schizophrenia 
are 7; DRD2, DRD3, DRD4, HTR1A, HTR2C, HTR3A, DRD1. The side 
effects of Olanzapine are reduced attention, swelling, dizziness, blurred vision, 
weight gain, tremor, gastrointestinal discomfort and so on. The structure of 
Risperidone is benzisoxazole and its structure similar drug is the one, 
pliperidone with 14 targets. The common shared targets with the paired 
disease, Tourette syndrome –Schizophrenia are 7; HTR2A, DRD2, DRD3, 
DRD4, HTR2C, HTR1A, DRD1. The interaction drug is ziprasidone. The side 
effects of ziprasidone are NMS, CV/cerebrovascular adverse reaction (stroke), 
TD, metabolic changes (hyperglycemia), hyperprolactinemia, orthostatic 
hypotension, leukopenia, somnolence, seizure, priapism and so on. 
Ziprasidone is benzisoxazole derivative and does not have structure similar 
drugs and have 25 targets. Drugs that cause interactions between drugs due to 
the target parameter are mainly olanzapine and risperidone, and have an 
interaction with fluphenazine via DRD2. The common targets with the paired 
disease, Schizophrenia-Tourette syndrome are 5; DRD3, DRD4, HTR1A, 
HTR2C, HTR3A. The side effects of ziprasidone are QT prolongation, NMS, 
TD, metabolic changes (CV/cerebrovascular risk, hyperglycemia, 
dislipidemia, weight gain), orthostatic hypotension, leukopenia, seizure, 
dysphagia, hyperprolactinemia, priapism, temperature control abnormality 
and so on. 
The next is by gathering the information of the drugs which have been 






common genes of albinism-melanoma are relatively small as 10, since there is 
no permitted treatment for albinism, in real it seems like Methoxsalen is used 
as off-label. It is worth studying to see whether Methoxsalen permitted for 
vitiligo and proriasis is effective and safe when used for albinism. The drug, 
methozsalen, commonly used for albinism-melanoma has a structure of a 
benzopyran of series furanocoumarin. The target of the drug is DNA and the 
drugs cause interactions are 7; ethotoin, fosphenytoin, mephenytoin, 
phenytoin, tacrine, thiothixene, tizanidine. Drug interactions mediated drug 
target, DNA relating to cross-linking/alkylation activity have 21 drugs 
(Pipobroman, Chlorambucil, Mitomycin, Streptozocin, Gemcitabine, Cisplatin, 
Oxaliplatin, Cyclophosphamide, Furazolidone, Dacarbazine, Temozolomide, 
Carboplatin, Cytarabine, Busulfan, Melphalan, Flucytosine, Procarbazine, 
Lomustine, Hydroxychloroquine, Trioxsalen, Thiotepa). The side effects of 
methoxsalen can be shown as hypotension, cardiovascular symptoms, 
arrhythmia, rash, allergy, pyrexia, nausea and dysgeusia. Methoxsalen has a 
permit for indications on vitiligo and psoriasis but using on albinism and 
melanoma is off-label use. Among 7 and 21 drugs, if they have the same side 
effects, similar structure and have an interaction mediated by target, these 
drugs realignment could be considered for the effectiveness on albinism and 
melanoma. 
In 21 drugs which cause drug interaction related to DNA cross-
linking/alkylation, trioxsalen has the same substructure with methoxsalen and 
side effects like blistering peeling of skin, reddened sore skin, swelling feet or 
lower legs, itching, nausea are shown similarly, because of skin cancer 
relevance the production was stopped in 2002. As part depigmenting product, 
Monobenzone, is permitted in the external application on vitiligo and the 






acid and mimosine. Treatments for melanoma are temozolomide, ipilimumab, 
peginterferon alfa-2b, aldesleukin, dacarbazine, and the drugs permitted for 
melanoma are 2 of ipilimumab, dacarbazine and others are used as off-label. 
The side effects of dacarbazine are Redness, pain, or swelling at place of 
injection, Black, tarry stools, blood in urine or stools, cough or hoarseness, 
accompanied by fever or chills, lower back or side pain, accompanied by 
fever or chills, painful or difficult urination, accompanied by fever or chills, 
pinpoint red spots on skin, unusual bleeding or bruising and the side effects of 
aldesleukin are agitation, confusion, diarrhea, dizziness, drowsiness, fever or 
chills, mental depression, nausea and vomiting, shortness of breath, sores in 
the mouth and on lips, tingling of the hands or feet, unusual decrease in 
urination, unusual tiredness or weakness, weight gain of 5 to 10 pounds or 
more. The side effects of Temosolimide can be shown amnesia, black, tarry 
stools, blood in the urine or stools, convulsions, cough or hoarseness, fever or 
chills, lower back or side pain, muscle weakness or paralysis on one or both 
sides of the body, painful or difficult urination, pinpoint red spots on the skin, 
swelling of the feet or lower legs and unusual bleeding or bruising. The side 
effects of Ipilimumab are bloody, black, or tarry stools, diarrhea, fever, 
heartburn, indigestion, itching skin, nausea, rash, severe stomach pain, 
cramping, or burning, unusual tiredness or weakness, vomiting, vomiting of 
material that looks like coffee grounds, severe and continuing watery or 
bloody diarrhea. The target drug of Temozolomide is DNA, Ipilimumab’s 
CTLA4, Peginterferon alfa-2b’s IFNAR1, IFNAR2, Aldesleukin’s IL2RB, 








Figure 2.1 Getting gene list associated with diseases from Genotator Genes of 
association score down to 1 for each disease were brought from Genotator and 







Figure 2.2 Shared genes in pairs of diseases. The figure shows a table of shared 










Figure 2.3 Process of gathering drug target from DrugBank. The figure above 










Figure 2.4 a) Excel Data of Drug information from DrugBank 
 







Figure 2.4 c) Build a drug-similarity network regarding side effects, targets, 
structures and interactions from the excel data of drug information 
 
















Figure 2.4 f) Merged Drug-Similarity Network 
 
Figure 2.4 Process of the drug-similarity network using Cytoscape. Figure 2.4 (a) 
through (f) shows how drug information gathered from DrugBank are organized and 

















CHAPTER  III.  RESULTS  
 
 
The information of genes related to the disease is found in an open 
access gene information databases like Genotator and common genes are 
found by pairing two diseases likely to be associated with each other. The 
drugs targeting common genes have the possibility to use for both sides of the 
diseases. In this study, the drugs which target common genes of 5 diseases 
pairs except the paired disease blood pressure- acute respiratory distress 
syndrome are examined and there are many cases that those are being used 
already for the other disease. Using the two stage examining method, after 
getting the  information about the drug that target common genes in between 
diseases from DrugBank, making drugs-similarity network and the by 
examining the common parts between drugs, a lot of things are in common 
other than target like side effects or interaction drugs. Through the drugs-
similarity network, it is able to determine the safety depending on the extent 
and the severity of the side effects and through the structure, common target 
drug interaction, the effectiveness can be validated. As the result of this study, 
I suggest the two stage examining method as protocol using protein-protein 
interaction network for realignment medications and using drugs-similarity 
network for realignment medications. The result of the study for each of 5 
paired diseases experimented according to the protocol is described below. 
Panic disorder has the biggest number of disease-related genes, 345 
only when it is seen the related score up to 1 on Genotator and Hypertension 






related genes. The common genes which are found in these pairs are 29 of 
Hypertension- Wegener's granulomatosis, 24 of Panic disorder-Alzheimer, 10 
of Albinism- Melanoma, 22 of Hypertension-Acute respiratory distress 
syndrome, 86 of Schizophrenia-Panic disorder and 25 of Tourette syndrome- 
Schizophrenia. The common genes shared in 6 paired diseases are pre-
organized on Table 3.1 and the Figure 3.12 the interaction between common 
genes-protein on Tourette syndrome- Schizophrenia is captured with 
confidence view. The Figure 3.13 is the collected information of drugs’ side 
effects from rxlist.com or drugs.com through DrugBank. In one paired 
diseases, Schizophrenia-Panic disorder has the biggest number of common 
genes; 86 of common genes are found when it uses calculated score 1 as the 
minimum standard. It enables to predict that there is a high possibility of 


















3.1 The Result of the paired diseases, 
Schizophrenia-Tourette syndrome 
 
Common related genes in Schizophrenia-Tourette syndrome chosen 
from Genotator are 25; BDNF, CNR1, CNTNAP2, COMT, DBH, DRD1, 
DRD2, DRD3, DRD4, GDNF, HLA-DRB1, HTR1A, HTR2A, HTR2C, 
HTR3A, IL10, IL10RA, IL1B, IL1RN, MAOA, OLIG2, SLC1A3, SLC6A3, 
SLC6A4, TNF (Table 3.1) and Figure 3.6 shows the interaction network of 
common genes in this paired diseases. Common drugs used for this paired 
diseases are Fluphenazine, Haloperidol, Olanzapine, Risperidone, Ziprasidone 
and the drug-similarity network is shown in Figure 3.14(b). Haloperidol is the 
only permitted for both Schizophrenia and Tourette syndrome, and the rest of 
4 have a permit for Schizophrenia’s indication yet is used for Tourette-
syndrome as off-label use. Because all four drugs Schizophrenia-Tourette 
syndrome common, many of side effects are shared in common, the off-label 
use seems reasonable. Table 3.2 shows briefly the each drug’s target, structure, 
interaction drugs and side-effects. 
The drugs used in these two diseases have each target in common 
causing drug interaction, the drugs which cause interaction mediated by 
DRD1A and DRD2 are all 5 of them, and especially DRD2 is the shared 
common gene in this paired diseases. Dopamine receptor D2 related 
medications are matched together and then by checking out if there is 
anything in common, the fact that side effects related to target are matched is 
confirmed. Drugs that cause weight gain, which can be led by metabolic 
abnormalities, are 4; fluphenazine, olanzapine, risperidone, ziprasidone and 







This relevance is confirmed in other references. When “DRD2 and 
weight gain” are searched on Pubmed 1,144 references are about the function 
of genes, 20 of them are related to weight gain and 8 out of them are about the 
relation between DRD2 and weight gain caused by the side effects by using 
psychiatry medication(Llerena et al., 2013; Houston et al., 2012; Lett et al., 
2012; Muleer et al., 2012; Lencz et al., 2010; Hong et al., 2010; Lencz and 
Malhortra, 2009; Malhortra, 2004). The gene related to Priapism caused by 
side effect is known as the α-1 adrenergic receptor (ADRA1A), Priapism is 
represented as the result of block effect of receptor when the drugs which 
have high affinity with this receptor are used. Olanzapine, Risperidone and 
Ziprasidone have ADRA1A as a drug target and all three are reported to have 
Priapism as side effect (Andersohn et al., 2010; Carruthers, 1994; Shahani, 
2012; Sinkeviciute, 2012). 
Among the drugs which are used in common for Schizophrenia-
Tourette Syndrome disease pair, the gene which is in common only in 
Haloperidol, Olanzapine, Risperidone and Ziprasidone is HTR2A and the 
suspicious side effects which related to this gene are TD, parkinsonism and 
movement disorder. There are many references associated with HTR2A about 
motor disturbance caused by the use of antipsychotic medication (Wilffert et 
al., 2009; Segman et al., 2001). Haloperidol is the highpotency drug which 
show extrapyramidal syndrome, low blood pressure and anticholin side effect 
on the patient who get more than 1%. The medication has less side effects yet 
has almost same effects is chosen in Psychiatric medications. In 
Schizophrenia’s known pathogenesis, Dopamine theory is the most influential 
and it is seen as dopaminergic bulimia status. Haloperidol’s pathogenesis is 
blocking D1, D2 receptor from the brain. Haloperidol’s targets are DRD2, 






Schizophrenia, DRD2, DRD3, HTR2A, DRD1 seem to get influenced. 
Though the pathogenesis of Tourette syndrome is not well known, if 
Haloperidol is applied for Tourette syndrome, the same genes DRD2, DRD3, 
HTR2A, and DRD1 seem to get influenced. Motor disturbance, TD and 
Parkinsonism by the effect of blocking DRD2 are expected. 
The targets of Fluphenazine are DRD2, DRD1A and Calmodulin and 
the clear effect of calmodulin was not found other than known dopamine 
receptor blocking effect. The drug targets of Olanzapine and Tourette 
syndrome related genes in common are 9; DRD2, HTR2A, DRD4, DRD3, 
HTR2C, DRD1, HTR1A, HTR3A 와 HTR2B. The targets which only related 
to Tourette syndrome are 2; HTR3A and HTR2B. There is a study which 
shows that the HTR3A function is related to fear disorder (Kondo et al., 2013) 
and this seems to be based on the study that HTR3A gene has the control 
function over fear or terror. There are the study that HTR2B is associated with 
the impulsive behavior (Bevilacqua and Goldman, 2013) and the study that 
examined how the mutation of HTR2B effect on the patients who have 
Tourette syndrome (Guo et al., 2012). Also there is study showing the relation 
between HTR2B and estrogen receptor-α (Kopparapu et al., 2013) and the 
study reports that it functions as homeostatic regulator of lactation (Collier et 
al., 2012). When olanzapine is used in Tourette syndrome, other than 
dopamine receptor blocking effect by acting as antagonistic with targeting 
HTR3A and HTR2B, as it is possible to control impulsive or fear, the 
improvement of Tic expressed in Tourette syndrome seems to be more helpful. 
The significant side effect of Olanzapine is weight gain and known to be 
related to HTR2C (Wallace et al., 2011). When Olanzapine or other drugs 
which target other HTR2C such as risperidone or ziprasidone are over used 






Among 14 drug targets of risperidone, the genes related to Tourette 
syndrome are 7; DRD2, HTR2A, DRD4, DRD3, HTR2C, DRD1, ADRA2A 
and the genes related to Schizophrenia are the same in 6; DRD2, DRD3, 
HTR2A, DRD4, HTR2C, DRD1 yet ADRA2A is the replacement gene of 
HTR1A. Among the targets of risperidone, the ones only related to Tourette is 
ADRA2A, which has one of adrenergic genes due to individual genetic 
polymorphism it is known to be related to obesity, diabetes, cardiovascular 
reactivity and ADHD. Out of 25 target genes of Ziprasidone, the genes have 
in common with Schizophrenia are 10; DRD2, DRD3, HTR2A, HTR6, DRD4, 
HTR2C, HTR3A, DRD1, HTR7, HTR1A and the genes related to Tourette 
syndrome are 7; HTR1B, DRD2, DRD4, DRD3, HTR2C, HTR1A, HTR3A 
and the drug target of Ziprasidone which relates to only Tourette syndrome is 
HTR1B only one. The side effects of Ziprasidone are drowsiness, headache, 
nausea, EPS, orthostatic hypotension, priapism and hyperprolactinemia. The 
side effects related to the function of HTR1B can be sexual symptom like 
anorgasmia, erectile dysfunction and priapism (Jóźków et al., 2013) and 
substance use disorder (Cao et al., 2013). The drugs which target the common 
genes, DRD2 and DRD1in 5 of common treatments for Schizophrenia-
Tourette syndrome are 94 and 11 each on DrugBank. The drugs targeting 
DRD2, which have both the similarity of drug structure(phenothiazine) and 
side effects (EPS, pseudoparkinsonism, TD, drowsiness, lethargy, restlessness, 
excitement, bizarre dreams, gynecomastia, increased libido, weight gain and 
so on) are 17; acetophenazine, carphenazine, chlorpromazine, fluphenazine, 
mesoridazine, methotrimeprazine, perphenazine, pipotiazine, prochlorperazine, 
promazine, promethazine, propiomazine, triethylperazine, thioproperazine, 
thioridazine, trifluoperazine and triflupromazine. By using D2 Dopamine 






and cause interaction are 49, and among them the drug has the same 
pyridopyrimidine structure with risperidone is Paliperidone and common side 
effects are headache, extrapyramidal syndrome, somnolence, dizziness, 
parkinsonism, insomnia, agitation and anxiety. The drugs which have the 
same structure of Phenothiazine with Fluphenazine are 17 and the side effects 
are drowsiness, hypotension, extrapyramidal syndrome, sedation and 
gynecomastia. The drug which has the same structure of phenylpiperidine 
with Haloperidol and is permitted as second alternative for Tourette 
syndrome; which has vocal and motor tics, is pimozide. The common side 
effects are tachycardia, postural hypotension and extrapyramidal syndrome. 
The drugs listed here, other than having permitted indication because 
they have DRD2 as common target, have structural similarity and side effects 
revelation occur equally, they can be considered high possible medication for 
realignment as treatment for diseases related to this gene. The permitted drug, 
haloperidol is for Tourette syndrome while pimozide is permitted to the 
patients with motor and phonic tic symptoms which is incurable, the target of 
this drug are 4; DRD2, DRD3, KCNH2, calmodulin. The common target of 
Haloperidol and Pimozide are DRD2, DRD3 and other 3 drugs, olanzapine, 
risperidone, ziprasidone target DRD2 and DRD3 as well. The drug which 
shares the same target which only Pimozide has is Fluphenazine, those two 
medications target Calmodulin and can show the same side effects such as 
EPS, drowsiness, restlessness and have similar structure of Benzene 
derivatives. Pimozide and fluphenazine can be used for both of diseases by 
targeting the genes shared in this paired disease and it can be seen that it has a 
common side effect in the target, only the two drugs that share. If not the 
temporal constraints, other drugs which act as an inhibitor for Calmodulin will 






cinchocaine, fluphenazine, trifluoperazine, loperamide, perphenazine, 
phenoxybenzamine, promethazine, pimozide, nifedipine and aprindine. 
Depending on the degree of affinity of the drug target, revealed expression 
level or frequency of side effects is a bit different from each other, but it 
seems to be predicted. Other than Haloperidol which has the permitted 
indications for Tourette syndrome, 4 other drugs(fluphenazine, olanzapine, 
risperidone, ziprasidone) used as off-label are shown to have more than two 
things in common on drugs-similarity network. As can be seen from the 
individual medical information(through DrugBank, rxlist.com or drugs.com), 
according to the degree of binding of the target, the expected effectiveness of 
medication, the severity or frequency of side effects can be known. In this 
study, these 4 medications used as off-label are individually used for each 
different Tic symptom and clinically effective to improve different symptoms, 
to avoid side effects according to the different profile of side effects, the fact 
that the drugs can be used selectively is proven theologically. 
With this method, the existing medications examined and checked if 
they can be used for other indications. First, because there is no alternative 
medication, the genes information of disease which use permitted medications 
for other diseases as off-label gets from public site, the gene database 
information, Genotator, and get the genes information of other diseases which 
share the same genes with the target of drugs used as off-label and then find 
out the shared genes between two diseases. STRING’s the protein-protein 
interaction network enables to see easily. Figure 3.1~3.6 show the interaction 
between shared genes from each paired disease in 6 paired diseases. As it is 
seen, the bold line means the level of closeness between genes. Second, the 
target protein the drugs which are used for two diseases is selected from 






for example, matching the target of treatment, sameness of the infrastructure, 
a common thing of side effects or the drug causes interactions, drugs-
similarity network can be made. Figure 3.14 (b) is drug-similarity network for 
the treatment of Schizophrenia-Tourette syndrome. Based on this network, 
phenothiazine structure is in common and the side effects commonly 
expressed in this structure, weight gain, priapism, tardive dyskinesia, 
parkinsonism, movement disorder, extrapyramidal syndrome, hypotension are 
revealed according to the degree and the 17 drugs which target DRD2 can be 
seen the candidate of medication for Tourette syndrome other than 
Schizophrenia. Since Fluphennazine is used as off-label, through the stage of 
clinical experiment, after confirming the safety and effectiveness, it can be 
used as permitted one. The effectiveness for Tourette syndrome can be 



















3.2 The Result of the paired diseases, 
Schizophrenia-Panic Disorder 
 
The shared genes in the paired diseases Schizophrenia-Panic disorder 
are 86; (ABCB1, ACE, APOE, ASTN2, BDNF, CCK, CCKAR, CHRM1, 
CHRM2, CHRNA7, CHRNB2, CNR1, CNTF, CNTNAP2, COMT, DAOA, 
DBH, DISC1, DLG1, DRD1, DRD2, DRD3, GABBR1, GABRA5, GABRB2, 
GABRG2, GABRG3, GABRR1, GAD1, GAD2, GDNF, GNB3, GRIA1, 
GRIA2, GRIA3, GRIA4, GRIK3, GRIK4, GRIN2A, GRIN2B, GRM3, 
GRM4, GRM5, HTR1A, HTR2A, HTR2C, HTR3A, HTR3B, HTR4, HTR5A, 
HTR6, HTR7, IL10, L1CAM, LEP, LEPR, MAOB, NCAM1, NEUROG1, 
NOS1, NPY, NRG1, NRG2, NRG3, NRXN1, NSF, NTF3, NTRK3, PDE4B, 
PDYN, PPP1R1B, RELN, RGS2, S100B, SLC1A1, SLC1A2, SLC1A3, 
SLC6A3, SLC6A4, SLC6A9, SNAP25, SNAP29, TPH1, TPH2) and is 
organized in Table 3.1. Among the 12 drugs which used for either 
Schizophrenia or Panic-disorder, except CHRM1which is the target of all the 
drugs, the drugs which shared DRD2, HTR2A, ADRA1A, HRH1, HTR2C are 
9; chlorpromazine, loxapine, aripiprazole, clozapine, olanzapine, quetiapine, 
ziprasidone, imipramine, desipramine and the drugs which shared SLC6A4 
are 6; loxapine, paroxetine, citalopram, escitalopram, imipramine, 
desipramine. Among these 6 medications, Paroxetine is the only permitted 
drug for panic disorder and among other shared drugs targeting SLC6A4, 
Citalopram is the only permitted one for depression, yet it is used for 
dementia-associated agitation and smoking cessation, ethanol abuse, 
obsessive-compulsive disorder (OCD), and diabetic neuropathy as off-label. 
Escitalopram is permitted for depression and anxiety, yet is used for dementia-






permitted only for depression yet are used for peripheral neuropathic pain, 
panic disorder as off-label. The side effects of these drugs including 
Extrapyramidal syndrome are stomach pain, blurred vision, cough or 
hoarseness, loss of appetite, loss of bladder control, difficult urination. 
Because the side effects can have different degree of revelation depending on 
individual, if the degree appeared to be severe and consistent while 
monitoring, try to find the best suited ones by changing with other drugs 
which have side effect profile. The gene which has high relation with Panic 
disorder is SLC6A4, rather than non-specific drugs because of too many 
shared genes, Loxapine permitted for Schizophrenia targeting SLC6A4 
primarily can be considered realignment for panic disorder. The drugs which 
cause interaction have a lot in common as it was shown in drug-similarity 
network (Figure 3.14 (a))and have these side effects, irregular heartbeats, loss 
of appetite, dizziness, trouble swallowing, priapism, drooling, colored stools, 
blurred vision, can be expressed in common. In paired disease, the permitted 
loxapine for Schizophrenia has SLC6A4 as drug target, and because there are 
a lot of interactions and side effects in common, it can be the candidate 














3.3 The Result of the paired diseases, 
Hypertension-Wegener Granulomatosis 
 
The shared related genes in the paired diseases Hypertension-Wegner 
granulomatosis are 29; SERPINA1, CTLA4, ACE, TNF, IL10, TGFB1, HLA-
DRB1, LEPR, GHRL, LEP, CCR5, IL1B, MS4A2, CD40, CCL5, HLA-DPB1, 
IL1RN, UCP2, PPARA, PPARG, NOD2, HLA-DQB1, C5, SERPINE1, 
SERPINA3, CIITA, F5, F2 and the per-mitted medication for Wegner 
granulomatosis is Rituximab, its representative target is MS4A1 and the drugs 
which have interactions using this target as mediator are ibritumomab, 
obinutuzumab and tositumomab. The drug which causes interaction in 
common is Trastuzumab. The drugs which target the gene, TNF related to 
Wegner Granulomatosis are 7; etanercept, infliximab, adalimumab, 
golimumab, certolizumab-pegol, pomalidomide and amrinone, and Etanercept 
and infliximab are used for vasculitis, Wegener Granulomatosis as off-label. 
The structure of drugs except Obinutuzumab is provided on DrugBank, and 
shown on Figure 3.7~3.11. As it is shown in drug-similarity network of this 
paired diseases (Figure 3.14 (c)), the side effects- abdominal pain, back pain, 
black, tarry stools, blurred vision-can be expressed in common and in the 
drugs which have TNF as shared target, etanercept, infliximab and 
adalimumab have drug interaction with tofacitinib and trastuzumab. Based on 
these, ibritumomab, obinutuzumab, tositumomab, etanercept, infliximab and 
adalimumab can be considered as the candidate medications for repositioning 








3.4 The Result of the paired diseases, Panic 
Disorder-Alzheimer Disease 
 
The paired diseases, Panic disorder-Alzheimer disease have 24 of 
shared genes- ABCB1, ACE, ACHE, AGTR1, ALDH2, APOE, AR, BDNF, 
CHAT, CHRNA7, CHRNB2, CLU, COMT, DRD3, GRIA1, GRIN2B, 
HTR2A, HTR2C, IL10, MAOA, NOS3, NTF3, RELN, SLC6A4- and in the 
drugs permitted for one disease, donepezil, paroxetine and desipramine have 
HTR2A as a shared target and the drugs which cause interaction are 
isocarboxazid, moclobemide, phenelzine, tolterodine, tranylcypromine, 
trazodone, trimipramine, triprolidine and zuclopenthixol. The information of 
medications which are used for the paired diseases, Panic Disorder-Alzheimer 
Disease is shown briefly in Table 3.3. The drugs which have the same 
structure of piperidines are donepezil and paroxetine. The drug-similarity 
network of the paired diseases is shown on Figure 3.14 (d) and the shared side 
effects are photosensitivity, difficult urination, blurred vision, loss of bladder 
control, galactorrhea and loss of appetite. Although Paroxetine is the drug 
permitted for depression and panic disorder, it is used for impulse control 
disorders and appetite disorders, dementia, anxiety-related symptoms and 
vasomotor symptoms of menopause as off-label. The fact that Paroxetine is 
used for agitation related to dementia as off-label can be confirmed on 
DrugBank and other DB of drugs information. Paroxetine was used for 
improving vasomotor symptoms of menopause as off-label now it is permitted 
to sell with indication. The drug named Brisdelle, which has indication for 
depression is paroxetine, was permitted to sell in November, 2013 by 
changing the target for vasomotor symptoms of menopause (hot flashes). 






1/3~1/7 of the amount (20-50mg/day) for depression. The side effects are 
when the amount for depression taken, asthenia, sweating, nausea, decreased 
appetite, somnolence, dizziness, insomnia, tremor, nervousness, ejaculatory 
disturbance, and other male genital disorders are revealed in more than 5 % of 
rate, and when 7.5mg of the amount for menopause is used, headache, fatigue, 
malaise, lethargy, nausea and vomiting can be revealed in more than 2% of 
rate. Thus, depending on the amount of intake, the kinds of side effects are 
more revealed and the degree of revelation is severer. Therefore intake of only 
the amount of necessary with the right way for the purpose is effective and is 
the best way to reduce side effects. As can be seen in individual cases, after 
the cumulative post-marketing experience with the drug, there are side effects 
are become known. When the effects unknown about medications and the 
problems from different dosage and capacity are experienced in the field, with 
the form of case report starts being reported and at the end, through clinical 
experiences, it gets the permit which is different from existing use. In the 
middle of the process, this is the study that reviewing process systematically if 
it is theologically reasonable to use off-label experimentally. 
From this point of view, paroxetine is being used for agitation by 
dementia as off-label is effective. The reason is that as antagonist works on 
Sodium-dependent serotonin transporter (SLC6A4), the effect can be caused. 
On the other hand, from the safety side, as antagonist works on muscarinic 
acetylcholine receptor (CHRM1), anticholine effects (constipation, dry 
mouth) can be revealed. When it is changed the amount used for anxiety, 
20~50mg/day into 10mg/day for the old, expected side effects can be 
headache, fatigue, weakness, nausea and vomiting. About safety, the 
frequency and variety of side effects are expected less than when it is used as 






alternatively for neuralgia, refractory anxiety, or hyperactivity disorder 
(ADHD) as off-label. As this drug works as inhibitor for SLC6A4 and 
CHRM1, is seems to be effective on improving anxiety related to dementia. 
From the aspect of safety, when the amount for the old, 25~100mg/day 
(maximum 150mg/day) is used, fatigue, lethargy, sedation and anticholine 


























3.5 The Result of the paired diseases, Albinism-
Melanoma 
 
Shared gene are ten as ASIP, HERC2, IRF4, MC1R, OCA2, SLC24A4, 
SLC24A5, SLC45A2, TYR, TYRP1 in Albinism-Melanoma paired disease 
and the protein interaction network is showed on Table 3.3. There are two 
drugs, methoxsalen and monobenzone, for vitiligo. There are 2 drugs called as 
Azelaic acid, Monobenzone targeting TYR in the shared gene of the paired 
diseases. The Azelaic acid is a permitted drug for acne vulgaris as a part 
external drug and the monobenzone is permitted for vitiligo. Burning, tingling, 
itching, redness or swelling of treated skin might appear as side effects of 2 
drugs. The things in common of the target and side effects can be seen using 
drug-similarity network and both can be considered realigning for albinism 
and melanoma treatment. The drugs used for Melonama are 5; temozolomide, 
dacarbazine, aldesleukin, ipilimumb, and vemurafenib, just ipilimumab and 
dacarbazine are permitted for melanoma and 3 others are being used as off-
label drugs. The drug similarity network is shown in Figure 3.14 (e). If the 
effectiveness of drugs used as off-label is examined, only temozolomide has 
the same target DNA with dacarbazine permitted for melanoma, the structure 
is similar to imidazole and trastuzumab is shared as the interaction drug. In 
the safety aspect, amnesia, blood urine, convulsions, cough or hoarseness, 
fever or chills, back pain, muscle weakness and painful urination can appear 
in temozolomide and in dacarbazine, colored stools, blood in urine, cough or 
hoarseness, fever or chills, back pain, painful urination appear as almost 
similar side effects. It is considered to be safe if it is examined from drug-
similarity network, because Temozolomide can be realigned for the treatment 






within range of prediction. 
In the 5 paired diseases listed above, the drugs used as off-label use are 
re-viewed with the genes-medicated, which are provided on Genotator, the 
drug which targets shared gene in a paired diseases is not only a treatment for 
permitted side of diseases but also it is effective to the other side disease as 
well. It means that realignment of drugs can be done with this way. In addition, 
after collecting the information of structures, targets, side effects, and 
interactive drugs on DrugBank and then create the similar networks with 
Cytoscape, there are a lot of cases that are overlapped more than twice in the 
similarities of the drugs in paired diseases. The relation of side effects 
revelations by targets can be confirmed and possibility for treatments for 
different diseases can be checked by having shared targets. Based on this, not 
only for checking the effectiveness and safety for the permitted existing drugs 
but also for searching new indication, bioinformatics is suggested as new 
protocol and once the protocol was applied as trial, off-target use was 
included considerably. The protocol is considered verified. The studies so far 
were basic and non-complete ones; mainly about the drugs used as off-label 
use, checking targets and examining side effects. However, if the studies 
continued to be done, bioinfomatical reviewing would reduce economical 
efforts and time in the development of new medications. 
Analyzing the information of genes between from Genotator and from 
STRING, using the information of drugs from DrugBank and Cytoscape, 








Table 3.1 Shared genes in pairs of diseases 
As a first step in finding therapeutic drug, diseases that share genes with targets of off label 
used drugs were paired. Then for each drug, genes of association score down to 1 were brought 
from Genotator and genes that are common were organized in table. 
pairs of disease shared genes 
Hypertension/Wegener 
Granulomatosis 
SERPINA1 CTLA4 ACE TNF IL10 TGFB1 HLA-DRB1 LEPR 
GHRL LEP CCR5 IL1B MS4A2 CD40 CCL5 HLA-DPB1 
IL1RN UCP2 PPARA PPARG NOD2 HLA-DQB1 C5 
SERPINE1 SERPINA3 CIITA F5 F2 
Panic disorder/Alzheimer 
ABCB1 ACE ACHE AGTR1 ALDH2 APOE AR BDNF CHAT 
CHRNA7 CHRNB2 CLU COMT DRD3 GRIA1 GRIN2B 
HTR2A HTR2C IL10 MAOA NOS3 NTF3 RELN SLC6A4 
Albinism/Melanoma 
ASIP HERC2 IRF4 MC1R OCA2 SLC24A4 SLC24A5 




ACE AGT APOE CALCA F5 GSTM1 GSTP1 GSTT1 HMOX1 
ICAM1 IL10 IL18 IL1RN IL6 LTA MTHFR NOS3 PLA2G7 
SCGB1A1 SERPINE1 TNF VEGFA 
Schizophrenia/Panic disorder 
ABCB1 ACE APOE ASTN2 BDNF CCK CCKAR CHRM1 
CHRM2 CHRNA7 CHRNB2 CNR1 CNTF CNTNAP2 COMT 
DAOA DBH DISC1 DLG1 DRD1 DRD2 DRD3 GABBR1 
GABRA5 GABRB2 GABRG2 GABRG3 GABRR1 GAD1 
GAD2 GDNF GNB3 GRIA1 GRIA2 GRIA3 GRIA4 GRIK3 
GRIK4 GRIN2A GRIN2B GRM3 GRM4 GRM5 HTR1A 
HTR2A HTR2C HTR3A HTR3B HTR4 HTR5A HTR6 HTR7 
IL10 L1CAM LEP LEPR MAOB NCAM1 NEUROG1 NOS1 
NPY NRG1 NRG2 NRG3 NRXN1 NSF NTF3 NTRK3 PDE4B 
PDYN PPP1R1B RELN RGS2 S100B SLC1A1 SLC1A2 




BDNF CNR1 CNTNAP2 COMT DBH DRD1 DRD2 DRD3 
DRD4 GDNF HLA-DRB1 HTR1A HTR2A HTR2C HTR3A 







Table 3.2 Schizophrenia-Tourette Syndrome Drug Information 
 
fluphenazine haloperidol olanzapine risperidone ziprasidone 
target 
DRD2                                                                                                                                                                                                    
DRD1A                                                                                                                                                                                           
calmodulin 
DRD2                                                                                                                                                                                                     
DRD1A                                                 
NMDA2B                                                                                                                                               































































M1, M2, M3, 
M4, M5 
interaction 
Amphetamine                                                                                                                                                                               















Donepezil                                                                                                                                                                                           



















































Five drugs that are off-label used for Tourette Syndrome that are originally approved for 
Schizophrenia were analyzed by target, interaction, structure, and side effects based on the data 




























































































































Table 3.3 Panic Disorder-Alzheimer Drug Information 
Drug information of those used for Panic disorder-Alzheimer were gathered from DrugBank 
and analyzed. 
drug donepezil paroxetine desipramine 










ADRA1D), CHRM1, CHRM2, 
CHRM3, CHRM4, CHRM5, 




loss of appetite 
muscle cramps 
nausea 








































cough or hoarseness 
dark urine 
dizziness 
 dry mouth 
irregular heartbeat or pulse 
inability to move 
inability to speak 
irritability 
light-colored stools 
loss of appetite 










































Figure 3.1 Protein-protein interaction network of the disease related genes 
shared by Hypertension and Wegener Granulomatosis. Of the genes that are 
related to Hypertension and Wegener Granulomatosis, common genes of association 
score down to 1 were brought from Genotator. Then, a network of association 
between the shared genes in this pair of diseases were drawn using STRING. The 
figure above is an interaction network of the 29 common genes in confidence view in 








Figure 3.2 Protein-protein interaction network of the disease related genes 
shared by Panic disorder and Alzheimer disease. The figure above shows 
correlation between the 24 disease related genes that are common in Panic disorder 











Figure 3.3 Protein-protein interaction network of the disease related genes 
shared by Albinism and Melanoma. The figure above shows correlation between 








Figure 3.4 Protein-protein interaction network of the disease related genes 
shared by Hypertension and Acute Respiratory Distress Syndrome. The figure 
above shows correlation between the 22 disease related genes that are common in 








Figure 3.5 Protein-protein interaction network of the disease related genes 
shared by Schizophrenia and Panic disorder. The figure above shows correlation 
between the 86 disease related genes of association score down to 1 from Genotator 








Figure 3.6 Protein-protein interaction network of the disease related genes 
shared by Tourette syndrome and Schizophrenia. The figure above shows 
correlation between the 25 disease related genes that are common in Tourette 
























Figure 3.9 Protein Structure of tositumomab from DrugBank (Harris et al., 





























Figure 3.12 Protein-protein interaction network depicted as confidence view. The 
figure above shows the interaction network between the 25 disease related genes that 








Figure 3.13 Collecting the side effects of drugs through DrugBank and unifying 
terms of the side effect. Editing side effects data of drugs from DrugBank that were 
duplicated or worded differently. It was necessary to unify the terms in order to 


















































Figure 3.14 Drug-similarity network (e) drugs for Albinism and Melanoma. 
A hexagon represents a drug prescribed for a specific disease. A rectangle, 
parallelogram, triangle and diamond indicate a drug target, a drug that interact with 









CHAPTER  IV.  DISCUSSION 
 
 
Some genes related to diseases of off-label use of drugs are well known, 
while other areas are still in an elementary level. Though drugs are used as 
off-label use, some diseases that do not have any information about the genes 
related to pathogenesis couldn’t help but be excluded. That is why small and 
trial 6 of paired diseases were made.  
Although the safety and effectiveness of some medications for rare 
incurable diseases can be checked with this study method, there is not much 
genetic information related to rare incurable diseases at this point. This is the 
regretful point and the actual reason to limit the scale of study as small. To use 
Bioinformatics properly, when the genetic information related to diseases 
should be found first, saved as data and accumulated continuously, it will be 
useful to find and develop medications quickly. Openness is another necessary 
element for the studies using bioinformatics methods. Accumulated genetic 
information and drugs information should be provided in various database 












CHAPTER  V. 




In this study, the information of genes about diseases aimed to be 
treated with off-label use is brought from Genotator, which is still limited. It is 
very difficult to get any information about incurable diseases such as Vitiligo, 
psoriasis, GVHD, Bell's palsy, delirium, Impulse control disorder, uveitis, 
lupus, multiple myositis, and scleroderma. The reason is that it might be 
uncertain for pathogenesis of diseases so far. In fact, the information of 
diseases for psychiatry and autoimmune disease is rarely known. There is the 
information about drugs permitted and off-target use of drugs as well in 
DrugBank. However, it just informs the use experimentally. Sometimes, 
although there are lots of grounds references and theological basic for off-
label use, due to economic reasons, without additional permission for 
indication of drugs, some drugs are used continuously as off-label use. 
However, many drugs are still used with only the result of clinical experiences 
with unclosed action mechanism. In the cases when pathogenesis of diseases, 
related genes, the target of treatment drugs and action mechanism are well 
known, even the use of off-label use can be proved to be effective and safety 
prediction can be achieved more accurately. As defined by Wikipedia, 
DrugBank is the online open access database which provides bio information 






pharmacological and pharmaceutical information) of medications. Although it 
is extensive, it plays of basic role as provider of the information of existing 
drugs helps to discover and realign medications for rare incurable diseases or 
new diseases. The experts’ part is to select and process the database provided 
and re-analyze that. In bioinformatics  approach methods which develop new 
indications of drugs, using the analysis of the binding site structure, find off-
label use or by using the inverse interrelation between unstable genes led by 
medications and genes unstable related to the diseases, find treatments; 
chemical systems biological approach; predicting indication with side effects 
named, Naïve Bayes. However, these methods usually just suggested a couple 
of new indications. It does not seem to be any studies that the work to try and 
confirm many medications for various diseases unlike what this study shows. 
Trying repositioning medications with bioinformatics methods, in many 
angles, by the larger number of pharmaceutical experts is considered very 
positive from the public health aspect and saving the cost. 
As there are two stages studied in this research, in the first stage, 
protein-protein interaction network was created by finding common genes 
between paired diseases. If there are drugs which target the protein of shared 
genes, it becomes candidate medication for repositioning. In the second stage, 
drug-similarity network was created for the drugs which target genes from the 
network created in the first stage. This network is the information of the drugs 
which target shared genes found in the first stage; about structure other than 
targets, interacting drugs and side effects. The drug-similarity network is to 
confirm the safety and effectiveness for realignment of medications. Rare 
diseases that should use off-label use or the genes related to incurable diseases, 
that existing drugs are hardly effective are from Genotator and in off-label 






discovered. 6 paired diseases are made and the number of shared genes in 
each paired disease; Wegener Granulomatosis-Hypertension is 29, Panic 
disorder-Alzheimer is 24, Pigment deficiency-Melanoma is 10, Hypertension-
Acute Respiratory Distress Syndrome is 22, Schizophrenia-Panic Disorder is 
86 and Tourette syndrome-Schizophrenia is 25 are determined. Relation 
analyzing for shared genes is done with STRING and protein-protein 
interaction network is gained. In these paired diseases, the drugs which target 
shared genes used as treatment are used for both diseases in many cases. In 
the second stage, the drugs used for those 6 paired diseases are whether 
permitted or off-label use without concerning, take the information of drugs 
and target genes from DrugBank and make drug-similarity network. The 
information collected this way is target of the drug, structure, the drug causing 
interaction (in particular the interaction target-mediated) and side effects. 
Drug-similarity network is visualized in drawing using Cytoscape to make 
shared elements are well seen. 
In 6 paired diseases, HTN-ARDS is excluded because acute respiratory 
distress syndrome is emergent and the information of drugs used as off-label 
use is too wide. In 5 paired diseases, the drugs which used as off-label use for 
each disease are examined with genes which are provided from Genotator as 
mediation, the drug which targets the shared gene in paired diseases is not 
only the treatment for the one permitted disease but also effective to the other 
one, therefore this way repositioning medication can be done. On DrugBank, 
about the drugs used as treatment for paired diseases, collect the information 
of the structure, target, side effects and medication interaction of drugs and 
create similarity network using Cytoscape; In many cases, the similarity of 
drugs used in one paired diseases are overlapped more than two. The 






possibility of treating other diseases is confirmed. Based on this, not only for 
checking the effectiveness and safety for the permitted existing drugs but also 
for searching new indication, bioinformatics is suggested as new protocol and 
once the protocol was applied as trial, off-label use was included considerably. 
The protocol is considered verified. The studies so far were basic and non-
complete ones; mainly about the drugs used as off-label use, checking targets 
and examining side effects. However, if the studies continued to be done, 
bioinfomatical reviewing would reduce economical efforts and time in the 
development of new medications. 
The recent example of the drug that used to be off-label use and now 
permitted indication is Rituximab, this one had only indications for use of 
lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, in April, 2011, 
and it got permitted for Wegener-Granulomatosis and microscopic bundles 
vasculitis. Rituximab has 12 drug targets and it was effective clinically for 
Wegener Granulomatosis and microscopic bundles vasculitis using MS4A1 as 
the main target. The other drugs that use MS4A1 as target; ibritumomab, 
obinutuzumab, tositumomab, are made drug-similarity network to see if they 
are effective on Wegener-Granulomatosis and microscopic bundles vasculitis. 
The result is that obinutuzumab doesn’t have any information about 
interaction, ibritumomab and tositumomab have the same drug, trastuzumab 
which causes interaction with Rituximab and non-special side effects such 
pain, chills, fever, cough and dizziness in common. Since the drug target of 
Ibritumomab and tositumomab is MS4A1, the drug causes interaction is the 
same and the profile of side effects is similar, it can be repositioned for 
Wegener-Granulomatosis and microscopic bundles vasculitis like rituximab. 
The other drugs used as off-label use for Wegener-Granulomatosis are 






related gene to Wegener-Granulomatosis is TNF and the interaction drugs 
caused by effect that blocks this target are overlapped as adalimumab and 
infliximab and the drugs affect on each drug’s effectiveness are in common as 
Rilonacept and Trastuzumab. The side effects are commonly revealed as chills, 
cough, abdominal pain and fever. Because of the things are in common, these 
3 drugs are effective to Wegener-Granulomatosis and do not seem to have any 
safety problems. In the paired diseases, Schizophrenia-Tourette syndrome, 
although four drugs fluphenazine, olanzapine, risperidone and ziprasidon 
which share the target and have common side effects are permitted only for 
Schizophrenia, when they are applied to Tourette syndrome as off-label use, it 
is proved to be safe and effective through drug-similarity network. The final 
confirmation of the safety and effectiveness for newly repositioned 





















This study is to show that using known drugs for different purpose is 
proper and safe with the bioinformatic methods. In bioinformatics, the study 
is processed with the terminology; repositioning of medication or change of 
use of medications and discovery new indicants of existing medications. The 
side effects discovered in the information of drug use could lead to the change 
of drug use or by finding drugs targeting the protein in the information of 
genes and realign them. The method used in this study starts with the drugs 
used as off-label use and how it is used as off-label use; in other words, it 
started from bringing the information of genes about indicated diseases from 
an open access database Genotator. The drug which enables to pair diseases 
was off-label use. Off-label use drugs  have permitted indications of certain 
diseases. The permitted diseases and diseases not permitted are paired, and the 
first stage is to look for the shared gene in each gene related to diseases. With 
these shared genes, protein-protein interaction network was created by genetic 
relation analysis program, called STRING. The proposal of this study is that 
medication in paired diseases used for one disease as treatment can be used 
for the other disease by shared gene-mediated and as the result, the fact that 
the drugs that target the shared gene have already used on both sides is 
confirmed. On the second stage, in the 6 of paired diseases, the list of 
permitted drugs and the off-label use is made and then takes the information 
of each drug from DrugBank. The information is about targets, side effects, 
interaction drugs and structures of drugs. The drug-similarity network is made 
with the information of 4 drugs using Cytoscape. In the network, the drugs 
that target the shared gene in paired diseases can be repositioned for the 






effects, structure or the drug causes interaction are in common, the safety and 
effectiveness can be confirmed. Through the bioinformatic methods, finding 
new indication from the existing medications, in pharmaceutical companies’ 
position, it is faster way to develop the new medications using less time and 
money and the possibility of success is fairly high. In the point of view of 
public health, under the situation that there is no treatment for rare incurable 
diseases, the off label drugs being used clinically can be used with 
confirmation of safety and the verification of effectiveness and through proper 
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생명정보학 기법을 이용한 기존 약물의  
새로운 적응증 탐색 연구 
 
이   영   미 
서울대학교 보건대학원 보건학과 
바이오인포매틱스 전공 
 
새로운 약물의 개발은 경제적으로 상당한 비용을 지불해야 하고 시
간적으로도 오랜 기간을 성공에 대한 보장 없이 투자해야 하는 쉽
지 않은 작업이다. 이제까지 개발되어 사용되고 있는 약물들에 대한 
정보는 과학기술의 발달, 특히 IT 기술의 발전으로 방대한 양이 축
적되어 있다. 이렇게 쌓인 정보는 사용 중인 약물의 안전성과 관련
하여 보다 철저히 약물을 점검할 수 있게 하였고, 만약 안전성에서 
문제가 확인되면 해당 약물을 시장에서 퇴출시키기도 하지만 새롭
게 부각된 부작용을 보는 시각을 전혀 달리하여 적응증을 바꾸어 
새로운 약물로 사용할 수 있게도 한다. 모든 약물의 작용기전과 타
깃 단백질이 명백히 밝혀져 있지는 않지만 과거에는 몰랐던 약물의 
정보들이 지금도 계속 연구되고 있고 이 연구들을 통해 찾아진 정
보들은 빅 데이터로 저장 되고 있다. 또한 생물에 대한 유전자 정보
도 밝혀지는 대로 계속 데이터베이스에 축적되면서 인류의 건강과 
생명연장을 위한 공적인 연구에 자유롭게 제공되고 있다. 탈리도마






지만 이제 부작용을 일으켰던 약물기전이 확인되면서 적응증을 새
롭게 바꾸어 다발성 골수종 치료제로 사용되고 있다. 이런 일이 가
능하게 된 것은 약물의 타깃과 질병 유발 관련 단백질에 대한 연구
가 충분히 이루어졌기 때문이다. 본 연구에서는 생명정보학적인 방
법을 이용해, 기존 약물들이 근거문헌이나 임상 시험 등이 별로 없
는 상황에서 치료대안이 없는 소아질환이나 희귀 난치성 질환 등에 
허가초과용도로 사용 되고 있는 현실에 비추어 그 사용의 유효성이 
있는지 보고, 지금까지 축적된 정보들을 바탕으로 안전성에는 문제
가 없는지 그 타당성을 살펴보고자 한다. 한편으로는 제약사들이 경
제적 이득이 없어 하려고 하지는 않지만 상당히 알려진 허가초과사
용에 이론적인 당위성을 부여해주고, 약물개발의 가장 첫 단계인 새
로운 물질의 새로운 적응증을 찾는 과정을 생명정보학적인 방법을 
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